Novel helicase-primase inhibitors
Thiazolyl amide derivatives address the limitations of current antiviral drugs by enhancing neuronal tissue penetration and targeting latent herpes viruses, providing a more effective treatment for herpes encephalitis and other severe infections.
Patent Information
- Application Number
- PCT/EP2026/063316
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-06-12
- Filing Date
- 2026-05-07
- Publication Date
- 2026-11-12
AI Technical Summary
Current antiviral drugs, including helicase-primase inhibitors like amenamevir and aminothiazoles, have insufficient efficacy to enter neuronal tissue or cross the blood-brain barrier, failing to effectively treat latent herpes viruses and prevent recurrent infections such as herpes encephalitis.
Development of thiazolyl amide derivatives with reduced carbonic anhydrase activity, improved solubility, and suitable pharmacokinetic profiles to target neuronal systems, allowing for effective treatment of severe herpes infections and latent viral reservoirs.
The thiazolyl amide derivatives provide sufficient exposure in neuronal tissues, inactivating latent herpes viruses and preventing recurrence, thus offering a more effective treatment for herpes encephalitis and other severe forms of herpes infections.
Smart Images

Figure EP2026063316_12112026_PF_FP_ABST
Abstract
Description
[0001] Innovative Molecules GmbH 07.05.2026
[0002] NOVEL HELICASE-PRIMASE INHIBITORS
[0003] SUMMARY OF THE INVENTION
[0004] The present invention relates to compounds acting as helicase-primase inhibitors (HPIs), to a process for their preparation and to their use as medicaments, in particular as antiviral medicaments, and to methods of using the same in the prophylaxis and treatment of herpes viruses, particularly herpes simplex infections and -mediated diseases.
[0005] BACKGROUND
[0006] The pandemic of herpes viral infections has plagued humanity since ancient times. Herpes simplex is a lifelong infection with high incidence and prevalence causing herpes labialis, genital herpes or herpes keratitis and, less frequently, life-threatening herpes encephalitis, meningitis or disseminated disease involving hepatitis and pneumonia. Probably every human is infected with at least one strain of human herpesviruses (HHV-1 to HHV-8) which poses a significant health burden worldwide. The prevalence of herpes simplex viruses (HSV-1) exceeds 60% in the general population, and HSV-2 infection rates are in the range of 15 to 30%. The alpha herpesviruses herpes simplex type 1 and 2 and varicella zoster virus (HHV-1 to HHV-3) are neurotrophic.
[0007] Disease symptoms often interfere with everyday activities and occasionally herpes simplex virus 1 and 2 (HSV-1 and HSV-2) infections are the cause of life-threatening (encephalitis), viral meningitis (e.g. Mollaret's meningitis) or sight-impairing disease (keratitis), especially in neonates, elderly and the immunocompromised patient population such as transplant or cancer patients or patients with an inherited immunodeficiency syndrome or disease. After primary infection episomal HSV DNA persists for life in a latent state in nuclei of neurons of trigeminal or dorsal root sensory ganglia. Periodic reactivation occurs thereafter upon diverse stimuli, resulting in the shedding of contagious infectious virus and recurrent disease, often resulting in significant psychosocial distress for the patient. At least 30% of patients experience recurrences for life. Currently no cure is available.
[0008] The first nucleosidic drugs used in antiviral therapy, idoxuridine and trifluridine, were launched in the 1960s and 1980s for the topical treatment of herpes keratitis but posed safety concerns. Vidarabine was launched in the 1970s for systemic therapy of herpes encephalitis. The development of Acyclovir (ACV) can be seen as a milestone in antiviral therapy, although Acyclovir has moderate efficacy it offers a remarkable safety profile. Since its approval in 1981, systemic administration of ACV became the gold standard of herpes simplex and varicella zoster therapy. Valacyclovir (VACV) and famciclovir (FCV), prodrugs of ACV, and its congener Penciclovir (PCV) designed to improve systemic exposure after oral administration, were introduced in the 1990s and provide more convenient dosing of once to twice a day as compared to ACV, which requires administration three to five times a day. In case of herpes encephalitis or neonatal herpes high doses of intravenous ACV have to be administered to achieve sufficient exposure of the prodrug in the brain. However, neither oral nor intravenous formulations thereof have an impact on the neuronal latent viral reservoir.So far, vaccines, interleukins, interferons, therapeutic proteins, antibodies, immunomodulators and small-molecule drugs with specific or non-specific modes of action lack either efficacy or the required safety profile to replace the nucleosidic drugs acyclovir, valacyclovir and famciclovir as the first choice of treatment.
[0009] At the dawn of the 21stcentury, a novel class of antiviral drug compounds was developed, acting as helicase-primase inhibitors (HPIs), which is based on a different mechanism of action. However, to date, only the helicase-primase inhibitor amenamevir is approved in Japan to treat herpes simplex and varicella zoster infections. Concerns about the use of amenamevir as a treatment option in diseases involving the ganglia or central nervous system have been published and in the clinic, amenamevir is not recommended for herpes infections of the central nervous system as summarized in Cureus 2022;16:e54775.
[0010] Further, there are currently aminothiazoles (e.g. pritelivir, HN0037, ABI-5366) and indoline derivatives (ABI-1179) for the treatment of herpes infections under development, which are the most potent drugs in development today. These antiviral agents also act by inhibiting the herpesviral helicase-primase, display low resistance rates in vitro and showed superior efficacy in animal models compared to nucleosidic drugs. However, at least for pritelivir, development is hampered by off target carbonic anhydrase activity, reduced neuronal tissue and brain penetration and an unusual pharmacokinetic profile, e.g. releasing an off-target, carbonic anhydrase active metabolite.
[0011] As mentioned above, alpha herpesviruses are neurotrophic viruses, which means that after infection they enter and settle in neuronal tissue leading to a persisting presence of these herpes viruses for life in neurons of the host in a latent form and a permanent neuronal exposure with the life-long risk of recurrent and periodically reactivating herpes infections. Such neuronal herpes virus exposure is further the cause of herpesvirus encephalitis (or herpes simplex encephalitis; HSE), which is thought to be caused by the transmission of herpes virus from a peripheral site on the face following HSV-1 reactivation or from neuronal tissue, along a nerve axon to the brain. The virus lies dormant in the ganglion of the trigeminal cranial nerve or in the neuronal tissue and gains access to the brain where it causes HSE.
[0012] The currently available treatment options with nucleosides are only moderately active reducing the course of the disease by one day in case of herpes labialis and genital herpes and reducing mortality of herpes encephalitis from 70 to 15% with high dose of intravenous acyclovir. The pitfall for the current treatment options is that the therapy has no impact on the key feature of herpes simplex viruses, namely efficacy in reducing recurrent disease from the latent viral reservoir in ganglia of the nervous system that has been established for life during primary infection in the infected host.
[0013] In general, sufficient target exposure of the active drug compound is necessary for efficacy. To improve treatment and potentially attenuate chronically persistent HSV infections, exposure in neuronal tissues and brain is essential but is difficult to achieve with nucleoside analogs such as ACV or helicase-primase inhibitors like amenamevir or pritelivir.It is therefore important to provide highly active antiviral drugs with sufficient exposure in the neuronal system offering better efficacy when treating herpes encephalitis and having an impact on the reactivation competence of the neuronal latent viral reservoir, thereby allowing to treat and inactivate or eliminate also latent herpes viruses in neuronal tissue and nerves and avoid recurrence and reactivation of herpes infections or even the severe implications like HSE.
[0014] Known antiviral drugs as e.g. amenamevir and the known aminothiazoles like pritelivir, have insufficient efficacy to enter neuronal tissue or to cross the blood-brain barrier to enter the brain and are therefore not able to provide an effective and eradicative cure for treating also latent or dormant forms of herpes viruses or even HSE.
[0015] PRIOR ART
[0016] Helicase-primase inhibitors based on aminothiazoles have been described e.g. in W02001 / 47904 (including Pritelivir) and in W02002 / 012211
[0017]
[0018] (WO2001 / 47904 - Pritelivir) (W02002 / 012211).
[0019] A novel class of antiviral drugs with helicase-primase inhibitory activity with improved properties is described in WO2017 / 174640, WO2019 / 068817, W02022 / 090409 and WO2023 / 135303 as well as in the scientific papers Sci. Transl. Med. 2021;13:eabf8668, Antivir. Res. 2021;195:105190 and Antivir. Res. 2023;219:105733, describing antiviral results of the helicase-primase inhibitor adibelivir (IM-250).
[0020] A further class of antiviral drug compounds with helicase-primase inhibitory activity are described in the international application W02024 / 049760 describing helicase-primase inhibitors with a cyclized urea moiety
[0021]
[0022] W02024 / 047508 and WO2024 / 224304 describe pharmaceutical compositions comprising the therein described “Compound 1” 2-(3-(2',5'-difluoro-[1,1'-biphenyl]-4-yl)-2-oxotetrahydro-pyrimidin-1(2 / - / )-yl)-4-methylthiazole-5-sulfonamide (ABI-5366):
[0023]
[0024] (ABI-5366)
[0025] Further helicase-primase inhibitor compounds based on indolinyl compounds are described in W02000 / 076966 and in WO2023 / 225162
[0026]
[0027] (W02000 / 076966) (WO2023 / 225162)
[0028] Further, compounds based on urea (like such as described in W02000 / 053591, W02024 / 047508 and WO2024 / 224304) and inverse amide structure elements (like such as described in W02002 / 012211), are suspected of having toxic potential by releasing aromatic amines, which have been described for their potential of causing bladder cancer.
[0029] Further helicase-primase inhibitor compounds are described in CN117247380
[0030]
[0031] DESCRIPTION OF THE INVENTION
[0032] One object of the present invention is to provide new antiviral compounds, acting as helicase-primase inhibitors, having efficacy against herpes viruses, particularly against herpes simplex viruses like HSV-1 and / or HSV-2 to provide novel drug compounds being suitable for the use in the prophylaxis and treatment of viral infections, like herpes infections such as herpessimplex infections, and -mediated diseases. In a further aspect, the new antiviral compounds should exhibit one or more of the properties comprising lack of (or at least significantly reduced) carbonic anhydrase activity, suitable solubility properties allowing to formulate the compounds in pharmaceutical compositions in the targeted administration form, a suitable pharmacokinetic profile including sufficient exposure of the active pharmaceutical ingredient (API) in the neuronal system offering efficacy for treating also severe forms of herpes infections like herpes encephalitis and offering treatment options against the reactivation competence of the neuronal latent viral reservoir, allowing to treat and inactivate or eliminate also latent herpes viruses in neuronal tissue and nerves and avoid recurrence and reactivation of herpes infections or even the severe implications like HSE, as well as safety, tolerability and stability under the relevant conditions, to make the compounds suitable for the preparation of and use as a medicament.
[0033] The present invention relates to thiazolyl amide derivatives of the general Formula (I):
[0034]
[0035] an enantiomer, diastereomer, tautomer, isotopic variant, / V-oxide, solvate and pharmaceutically acceptable salt thereof, wherein
[0036] L is a group forming a saturated or partially saturated C4-io-membered heterocycloalkyl-ring or a 6-membered heteroaryl-ring being characterized by the ring-forming group [-C-C(=O)- N-], wherein said ring L can optionally contain 1 or 2 additional heteroatoms selected from O, S or N, and wherein the heterocycloalkyl- and heteroaryl-ring “L” can optionally carry 1 to 4 additional substituents independently selected from the group consisting of oxo, -CN, - NO2, -OR11, -O-C2-6-alkylene-OR11, -Ci-6-alkyl, halo-Ci-6-alkyl, halogen, -CO2R11, - C(=O)NR11R12, -C(=O)NR11SO2R11, -C(=O)R11, -SR11, -SOXR11, -SO3R11, -P(=O)(OR11)2, - SO2NR11R12, -NR11C(=O)R11, -NR11SO2R13, -NR11C(=O)NR11R12, -NR11SO2NR11R12, -C3-10- cycloalkyl, -O-Cs-w-cycloalkyl, -C3-10-heterocycloalkyl, -O-C3-10-heterocycloalkyl and - NR11R12;
[0037] X is selected from
[0038]
[0039] R1is selected from H, halogen, Ci-6-alkyl, halo-Ci-6-alkyl, C3-6-cycloalkyl, halo-C3-6-cycloalkyl, -O-Ci-6-alkyl, -O-halo-Ci-6-alkyl and -NH-Ci-6-alkyl;
[0040] R2is selected from H, -CN, -NO2, -Ci-10-alkyl, -C2- -alkenyl, -C2- -alkynyl, -Co- -alkylene-Cs- 10-cycloalkyl, -Co-io-alkylene-C3- -heterocycloalkyl, -Co-w-alkylene-(5- to 10-memberedheteroaryl), -Co-w-alkylene-(6- to 10-membered aryl), -Co-w-alkylene-OR11, -Co-w-alkylene- CO2R11, -Co-io-alkylene-C(=0)NR11R12, -CO-io-alkylene-C(=S)NR11R12, -Co-10-alkylene- C(=O)NR11SO2R13, -Co-io-alkylene-C(=S)NR11S02R11, -Co-io-alkylene-C(=0)R11, -C0-10- alkylene-C(=S)R11, -Co-10-alkylene-SR11, -Co-io-alkylene-SOxR13, -Co- -alkylene-SOsR11, - Co-io-alkylene-S02NR11R12, -Co-io-alkylene-NR11C(=0)R11, -Co-io-alkylene-NR11C(=S)R11, - Co-io-alkylene-NR11S02R13, -Co-io-alkylene-NR11C(=0)NR11R12, -Co-10-alkylene- NR11C(=S)NR11R12, -Co-io-alkylene-NR11S02NR11R12, -Co-io-alkylene-NR11R12, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, -CN, -NO2, -OR11, -O-C2-6-alkylene-OR11, -Ci-6-alkyl, halo-Ci-6-alkyl, halogen, -CO2R11, -C(=O)NR11R12, -C(=O)NR11SO2R11, -C(=O)R11, -SR11, -SOXR11, - SO3R11, -P(=O)(OR11)2, -SO2NR11R12, -NR11C(=O)R11, -NR11SO2R13, -NR11C(=O)NR11R12, - NR11SO2NR11R12, -Cs-w-cycloalkyl, -O-Cs-w-cycloalkyl, -C3-10-heterocycloalkyl, -O-C3-10- heterocycloalkyl and -NR11R12;
[0041] R3is selected from H, -Ci-6-alkyl, halo-Ci-6-alkyl, -O-Ci-6-alkyl, -O-halo-Ci-6-alkyl, -C3-6- cycloalkyl and -C3-6-heterocycloalkyl, wherein alkyl, cycloalkyl and heterocycloalkyl are optionally substituted with 1 to 5 substituents independently selected from halogen, -CN, - OH, oxo, -C1-3-alkyl, halo-C1-3-alkyl, -O-Ci-3-alkyl, -O-halo-Ci-3-alkyl, -SO2-Ci-3-alkyl, -CO2H; or R2and R3when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, -CN, -NO2, -OH, oxo, -C1-3-alkyl, halo-C1-3-alkyl, -O-Ci-3-alkyl, -O-halo-Ci-3-alkyl, -SO2-Ci-3-alkyl, -CO2H; R5and R6are independently selected from H, halogen, -Ci-6-alkyl, -NH2, -NHCi-6-alkyl, -N(CI-6- alkyl)2, -Co-6-alkylene-C(=0)NH2;
[0042] or R5and R6independently when taken together with the carbon to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, -CN, -NO2, -OH, oxo, -C1-3-alkyl, halo-C1-3-alkyl, -O-Ci-3-alkyl, -O-halo-Ci-3-alkyl, -SO2-Ci-3-alkyl, - CO2H;
[0043] R7is selected from a phenyl and 5- or 6-membered heteroaryl, wherein phenyl and heteroaryl are optionally substituted with 1 to 4 substituents independently selected from halogen, - CN, -NO2, -OH, -Ci-6-alkyl, -O-Ci-6-alkyl, -C3-6-cycloalkyl, -O-C3-6-cycloalkyl, -C3-6- heterocycloalkyl, -O-C3-6-heterocycloalkyl, -SOy-Ci-6-alkyl, -CO2H, -C(=O)O-Ci-6-alkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -O-(6- to 10-membered aryl) and -O-(5- to 10-membered heteroaryl), wherein
[0044] alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with 1 to 5 substituents independently selected from halogen, -CN, -NO2, -OH, -R13, -OR13, - CO2R11, -NR11R12, -C(=O)R11, -C(=S)R11, -C(=O)NR11R12, -NR11C(=O)NR11R12, -NR11C(=O)OR13, -OC(=O)NR11R12, -C(=S)NR11R12, -NR11C(=S)NR11R12, NR11C(=S)OR13, -OC(=S)NR11R12; -SOy-C1-6-alkyl, -SOy-halo-C1-6-alkyl, -SR11, -SOXR13, -SO3R11, -SO2NR11R12, -NR11SO2R13, -NR11SO2NR11R12;
[0045] R8is independently selected from H, -CN, -NO2, -Ci-10-alkyl, -C2- -alkenyl, -C2- -alkynyl, -Co- io-alkylene-C3- -cycloalkyl, -Co-w-alkylene-Cs-io-heterocycloalkyl, -Co-w-alkylene-(5 to 10- membered heteroaryl), -Co-w-alkylene-(6 to 10-membered aryl), -Co-w-alkylene-OR11, -Co- w-alkylene-CO2R11, -Co-io-alkylene-C(=0)NR11R12, -CO-io-alkylene-C(=S)NR11R12, -C0-10- alkylene-C(=O)NR11SO2R13, -Co-io-alkylene-C(=S)NR11S02R11, -Co-io-alkylene-C(=0)R11, - Co-w-alkylene-C(=S)R11, -Co-10-alkylene-SR11, -Co-io-alkylene-SOx-R13, -Co-10-alkylene- SO3R11, -Co-io-alkylene-S02NR11R12, -Co-io-alkylene-NR11C(=0)R11, -Co-10-alkylene- NR11C(=S)R11, -Co-io-alkylene-NR11S02R11, -Co-io-alkylene-NR11C(=0)NR11R12, -Co-10- alkylene-NR11C(=S)NR11R12, -Co-io-alkylene-NR11-S02-NR11R12, -Co-io-alkylene-NR11R12, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, -CN, -NO2, -OR11, -O-C2-6-alkylene-OR11, -Ci-6-alkyl, halo-Ci-6-alkyl, halogen, -CO2R11, -CONR11R12, -CONR11SO2R11, -COR11, -SOXR11, -SO3H, -PO(OH)2, - SO2NR11R12, -NR11COR11, -NR11SO2R11, -NR11-CO-NR11R12, -NR11-SO2-NR11R12, -C3-10- cycloalkyl, -O-Cs-w-cycloalkyl, -C3-10-heterocycloalkyl, -O-C3-10-heterocycloalkyl and - NR11R12;
[0046] R9is selected from -Ci-10-alkyl, -C2- -alkenyl, -C2-io-alkynyl, -Co- -alkylene-Cs-io-cycloalkyl, - Co-io-alkylene-C3-10-heterocycloalkyl, -Co-w-alkylene-(5- to 10-membered heteroaryl), -C0-10- alkylene-(6- to 10-membered aryl), -Co-w-alkylene-OR11, -Co-w-alkylene-C02R11, -C0-10- alkylene-C(=O)NR11R12, -CO-io-alkylene-C(=S)NR11R12, -Co-io-alkylene-C(=0)NR11S02R13, - Co-w-alkylene-C(=S)NR11S02R11, -Co-io-alkylene-C(=0)R11, -CO-io-alkylene-C(=S)R11, -C0- 10-alkylene-SR11, -Co-w-alkylene-SOxR13, -Co-w-alkylene-SOsR11, -Co-w-alkylene- SO2NR11R12, -Co-io-alkylene-NR11C(=0)R11, -CO-io-alkylene-NR11C(=S)R11, -Co-10-alkylene- NR11SO2R13, -Co-io-alkylene-NR11C(=0)NR11R12, -Co-io-alkylene-NR11C(=S)NR11R12, -C0-10- alkylene-NR11SO2NR11R12, -Co-w-alkylene-NR11R12, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, -CN, -NO2, - OR11, -O-C2-6-alkylene-OR11, -C1-6-alkyl, halo-C1-6-alkyl, halogen, -CO2R11, -C(=O)NR11R12, -C(=O)NR11SO2R11, -C(=O)R11, -SR11, -SOXR11, -SO3R11, -P(=O)(OR11)2, -SO2NR11R12, - NR11C(=O)R11, -NR11SO2R13, -NR11C(=O)NR11R12, -NR11SO2NR11R12, -C3-io-cycloalkyl, -O- C3-io-cycloalkyl, -C3-10-heterocycloalkyl, -O-C3-10-heterocycloalkyl and -NR11R12;
[0047] R11is independently selected from H, -Ci-6-alkyl, -C0-6-alkylene-C3-10-cycloalkyl and -Co-6- alkylene-Cs-io-heterocycloalkyl, wherein alkyl, alkylene, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 6 substituents independently selected from the group consisting of halogen, -CN, -OH, oxo, -C1-3-alkyl, halo-C1-3-alkyl, -O-C1-3-alkyl, -O-halo-C1-3-alkyl, -NH2, -NH(C1-3-alkyl), -N(C1-3-alkyl)2, -C3-6-heterocycloalkyl, -C3-6-cycloalkyl, -SO2-NHC1-3-alkyl, -SO2-N(Ci-3-alkyl)2and -SO2-Ci-3-alkyl, wherein cycloalkyl andheterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of F, -OH, oxo, -CH3, -CHF2 and -CF3;
[0048] R12is independently selected from H, Ci-6-alkyl, halo-Ci-6-alkyl and C3-6-cycloalkyl;
[0049] or R11and R12when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, -CN, -NO2, -OH, oxo, -C1-3-alkyl, halo-C1-3-alkyl, -O-Ci-3-alkyl, -O-halo-Ci-3-alkyl, -SO2-Ci-3-alkyl, -CO2H; R13is independently selected from -Ci-6-alkyl, -C2-6-alkenyl, -C2-6-alkynyl, -Co-6-alkylene-C3- - cycloalkyl and -Co-6-alkylene-C3- -heterocycloalkyl, wherein alkyl, alkylene, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 6 substituents independently selected from the group consisting of halogen, -CN, -OH, oxo, -C1-3-alkyl, halo-C1-3-alkyl, - O-Ci-3-alkyl, -O-halo-Ci-3-alkyl, -NH2, -NH(Ci-3-alkyl), -N(Ci-3-alkyl)2, -C3-6-heterocycloalkyl, -C3-6-cycloalkyl, -SO2-NHCi-3-alkyl, -SO2-N(Ci-3-alkyl)2 and -SO2-Ci-3-alkyl, wherein cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of F, -OH, oxo, -CH3, -CHF2 and -CF3; n is selected from 0 and 1;
[0050] x is independently selected from 1 and 2;
[0051] y is independently selected from 0, 1 and 2.
[0052] In a further embodiment the present invention relates to thiazolyl amide derivatives of the general Formula (I):
[0053]
[0054] an enantiomer, diastereomer, tautomer, isotopic variant, / V-oxide, solvate and pharmaceutically acceptable salt thereof, wherein
[0055] L is a group forming a saturated or partially saturated C4-io-membered heterocycloalkyl-ring or a 6-membered heteroaryl-ring being characterized by the ring-forming group [-C-C(=O)- N-], wherein said ring L can optionally contain 1 or 2 additional heteroatoms selected from O, S or N, and wherein the heterocycloalkyl- and heteroaryl-ring “L” can optionally carry 1 to 4 additional substituents independently selected from the group consisting of oxo, -CN, - NO2, -OR11, -O-C2-6-alkylene-OR11, -Ci-6-alkyl, halo-Ci-6-alkyl, halogen, -CO2R11, - C(=O)NR11R12, -C(=O)NR11SO2R11, -C(=O)R11, -SR11, -SOXR11, -SO3R11, -P(=O)(OR11)2, - SO2NR11R12, -NR11C(=O)R11, -NR11SO2R13, -NR11C(=O)NR11R12, -NR11SO2NR11R12, -C3-10- cycloalkyl, -O-Cs-w-cycloalkyl, -C3-10-heterocycloalkyl, -O-C3-10-heterocycloalkyl and - NR11R12;X is selected from
[0056]
[0057] R1is selected from H, halogen, Ci-6-alkyl, halo-Ci-6-alkyl, C3-6-cycloalkyl, halo-C3-6-cycloalkyl, -O-Ci-6-alkyl, -O-halo-Ci-6-alkyl and -NH-Ci-6-alkyl;
[0058] R2is selected from H, -CN, -NO2, -Ci-10-alkyl, -C2- -alkenyl, -C2- -alkynyl, -Co- -alkylene-Cs- 10-cycloalkyl, -Co-io-alkylene-C3-10-heterocycloalkyl, -Co-w-alkylene-(5- to 10-membered heteroaryl), -Co-w-alkylene-(6- to 10-membered aryl), -Co-10-alkylene-OR11, -Co-w-alkylene- CO2R11, -Co-io-alkylene-C(=0)NR11R12, -CO-io-alkylene-C(=S)NR11R12, -Co-10-alkylene- C(=O)NR11SO2R13, -Co-io-alkylene-C(=S)NR11S02R11, -Co-io-alkylene-C(=0)R11, -C0-10- alkylene-C(=S)R11, -Co-10-alkylene-SR11, -Co-io-alkylene-SOxR13, -Co-w-alkylene-SOsR11, - Co-io-alkylene-S02NR11R12, -Co-io-alkylene-NR11C(=0)R11, -CO-io-alkylene-NR11C(=S)R11, - Co-io-alkylene-NR11S02R13, -Co-io-alkylene-NR11C(=0)NR11R12, -Co-10-alkylene- NR11C(=S)NR11R12, -Co-io-alkylene-NR11S02NR11R12, -CO-io-alkylene-NR11R12, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, -CN, -NO2, -OR11, -O-C2-6-alkylene-OR11, -Ci-6-alkyl, halo-Ci-6-alkyl, halogen, -CO2R11, -C(=O)NR11R12, -C(=O)NR11SO2R11, -C(=O)R11, -SR11, -SOXR11, - SO3R11, -P(=O)(OR11)2, -SO2NR11R12, -NR11C(=O)R11, -NR11SO2R13, -NR11C(=O)NR11R12, - NR11SO2NR11R12, -Cs-w-cycloalkyl, -O-Cs-w-cycloalkyl, -C3-10-heterocycloalkyl, -O-C3-10- heterocycloalkyl and -NR11R12;
[0059] R3is selected from H, -Ci-6-alkyl, halo-Ci-6-alkyl, -O-Ci-6-alkyl, -O-halo-Ci-6-alkyl, -C3-6- cycloalkyl and -C3-6-heterocycloalkyl, wherein alkyl, cycloalkyl and heterocycloalkyl are optionally substituted with 1 to 5 substituents independently selected from halogen, -CN, - OH, oxo, -C1-3-alkyl, halo-C1-3-alkyl, -O-Ci-3-alkyl, -O-halo-Ci-3-alkyl, -SO2-Ci-3-alkyl, -CO2H; or R2and R3when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, -CN, -NO2, -OH, oxo, -C1-3-alkyl, halo-C1-3-alkyl, -O-Ci-3-alkyl, -O-halo-Ci-3-alkyl, -SO2-Ci-3-alkyl, -CO2H; R5and R6are independently selected from H, halogen, -Ci-6-alkyl, -NH2, -NHCi-6-alkyl, -N(CI-6- alkyl)2, -Co-6-alkylene-C(=0)NH2;
[0060] or R5and R6independently when taken together with the carbon to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, -CN, -NO2,-OH, oxo, -C1-3-alkyl, halo-C1-3-alkyl, -O-Ci-3-alkyl, -O-halo-Ci-3-alkyl, -SO2-Ci-3-alkyl, - CO2H;
[0061] R7is selected from a phenyl and 5- or 6-membered heteroaryl, wherein phenyl and heteroaryl are optionally substituted with 1 to 4 substituents independently selected from halogen, - CN, -NO2, -OH, -Ci-6-alkyl, -O-Ci-6-alkyl, -C3-6-cycloalkyl, -O-C3-6-cycloalkyl, -C3-6- heterocycloalkyl, -O-C3-6-heterocycloalkyl, -SOy-Ci-6-alkyl, -CO2H, -C(=0)0-Ci-6-alkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -0-(6- to 10-membered aryl) and -0-(5- to 10-membered heteroaryl), wherein
[0062] alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with 1 to 5 substituents independently selected from halogen, -CN, -NO2, -OH, -R13, -OR13, - CO2R11, -NR11R12, -C(=0)R11, -C(=S)R11, -C(=0)NR11R12, -NR11C(=0)NR11R12, - NR11C(=0)0R13, -0C(=0)NR11R12, -C(=S)NR11R12, -NR11C(=S)NR11R12, NR11C(=S)0R13, -0C(=S)NR11R12; -SOy-C1-6-alkyl, -SOy-halo-C1-6-alkyl, -SR11, -SOXR13, -SO3R11, -SO2NR11R12, -NR11SO2R13, -NR11SO2NR11R12;
[0063] R8is independently selected from H, -CN, -NO2, -Ci-10-alkyl, -C2- -alkenyl, -C2- -alkynyl, -Co- lo-alkylene-Cs-w-cycloalkyl, -Co-w-alkylene-Cs-io-heterocycloalkyl, -Co-w-alkylene-(5 to 10- membered heteroaryl), -Co-w-alkylene-(6 to 10-membered aryl), -Co-w-alkylene-OR11, -Co- io-alkylene-C02R11, -Co-io-alkylene-C(=0)NR11R12, -CO-io-alkylene-C(=S)NR11R12, -C0-10- alkylene-C(=O)NR11SO2R13, -Co-io-alkylene-C(=S)NR11S02R11, -Co-io-alkylene-C(=0)R11, - Co-w-alkylene-C(=S)R11, -Co-10-alkylene-SR11, -Co-io-alkylene-SOx-R13, -Co-10-alkylene- SO3R11, -Co-io-alkylene-S02NR11R12, -Co-io-alkylene-NR11C(=0)R11, -Co-10-alkylene- NR11C(=S)R11, -Co-io-alkylene-NR11S02R11, -Co-io-alkylene-NR11C(=0)NR11R12, -Co-10- alkylene-NR11C(=S)NR11R12, -Co-io-alkylene-NR11-S02-NR11R12, -Co-io-alkylene-NR11R12, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, -CN, -NO2, -OR11, -O-C2-6-alkylene-OR11, -Ci-6-alkyl, halo-Ci-6-alkyl, halogen, -CO2R11, -C0NR11R12, -CONR11SO2R11, -COR11, -SOXR11, -SO3H, -PO(OH)2, - SO2NR11R12, -NR11C0R11, -NR11SO2R11, -NR11-CO-NR11R12, -NR11-SO2-NR11R12, -C3-10- cycloalkyl, -O-Cs-w-cycloalkyl, -C3-10-heterocycloalkyl, -O-C3-10-heterocycloalkyl and - NR11R12;
[0064] R9is selected from -Ci-10-alkyl, -C2- -alkenyl, -C2- -alkynyl, -Co-w-alkylene-Cs-io-cycloalkyl, - Co-io-alkylene-C3-10-heterocycloalkyl, -Co-w-alkylene-(5- to 10-membered heteroaryl), -C0-10- alkylene-(6- to 10-membered aryl), -Co-w-alkylene-OR11, -Co- -alkylene-C02R11, -C0-10- alkylene-C(=O)NR11R12, -CO-io-alkylene-C(=S)NR11R12, -Co-io-alkylene-C(=0)NR11S02R13, - Co-io-alkylene-C(=S)NR11S02R11, -Co-io-alkylene-C(=0)R11, -CO-io-alkylene-C(=S)R11, -C0- 10-alkylene-SR11, -Co-w-alkylene-SOxR13, -Co-w-alkylene-SOsR11, -Co-w-alkylene- SO2NR11R12, -Co-io-alkylene-NR11C(=0)R11, -CO-io-alkylene-NR11C(=S)R11, -Co-10-alkylene- NR11SO2R13, -Co-io-alkylene-NR11C(=0)NR11R12, -Co-io-alkylene-NR11C(=S)NR11R12, -C0-10- alkylene-NR11SO2NR11R12, -Co-w-alkylene-NR11R12, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is unsubstituted or substituted with1 to 7 substituents independently selected from the group consisting of oxo, -CN, -NO2, - OR11, -O-C2-6-alkylene-OR11, -C1-6-alkyl, halo-C1-6-alkyl, halogen, -CO2R11, -C(=O)NR11R12, -C(=O)NR11SO2R11, -C(=O)R11, -SR11, -SOxR11, -SO3R11, -P(=O)(OR11)2, -SO2NR11R12, - NR11C(=O)R11, -NR11SO2R13, -NR11C(=O)NR11R12, -NR11SO2NR11R12, -C3-io-cycloalkyl, -O- Cs-w-cycloalkyl, -C3-10-heterocycloalkyl, -O-C3-10-heterocycloalkyl and -NR11R12;
[0065] R11is independently selected from H, -Ci-6-alkyl, -C0-6-alkylene-C3-10-cycloalkyl and -C0-6-alkylene-C3-10-heterocycloalkyl, wherein alkyl, alkylene, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 6 substituents independently selected from the group consisting of halogen, -CN, -OH, oxo, -C1-3-alkyl, halo-C1-3-alkyl, -O-C1-3-alkyl, -O-halo-C1-3-alkyl, -NH2, -NH(C1-3-alkyl), -N(C1-3-alkyl)2, -C3-6-heterocycloalkyl, -C3-6-cycloalkyl, -SO2-NHC1-3-alkyl, -SO2-N(Ci-3-alkyl)2and -SO2-Ci-3-alkyl, wherein cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of F, -OH, oxo, -CH3, -CHF2and -CF3;
[0066] R12is independently selected from H, C1-6-alkyl, halo-C1-6-alkyl and C3-6-cycloalkyl;
[0067] or R11and R12when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, -CN, -NO2, -OH, oxo, -C1-3-alkyl, halo-C1-3-alkyl, -O-Ci-3-alkyl, -O-halo-Ci-3-alkyl, -SO2-Ci-3-alkyl, -CO2H; R13is independently selected from -Ci-6-alkyl, -C0-6-alkylene-C3-10-cycloalkyl and -Co-6-alkylene- Cs-io-heterocycloalkyl, wherein alkyl, alkylene, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 6 substituents independently selected from the group consisting of halogen, -CN, -OH, oxo, -C1-3-alkyl, halo-C1-3-alkyl, -O-C1-3-alkyl, -O-halo-C1-3-alkyl, -NH2, -NH(C1-3-alkyl), -N(C1-3-alkyl)2, -C3-6-heterocycloalkyl, -C3-6-cycloalkyl, -SO2-NHC1-3-alkyl, -SO2-N(Ci-3-alkyl)2and -SO2-Ci-3-alkyl, wherein cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of F, -OH, oxo, -CH3, -CHF2and -CF3;n is selected from 0 and 1;
[0068] x is independently selected from 1 and 2;
[0069] y is independently selected from 0, 1 and 2.
[0070] From the scope of the present invention, defining the compounds of the formula (I) as described anywhere herein, the following compounds are excluded:
[0071]
[0072] In the context of the present invention " C1-10-alkyl" means a saturated alkyl chain having 1 to 10 carbon atoms which may be straight chained or branched. Examples thereof include methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, heptyl, octyl, nonyl and decyl. Preferred is “Ci-6-alkyl”, more preferred is “Ci-4-alkyl”, most preferred is “Ci-3-alkyl”, a particularly preferred alkyl group is a methyl group (in particular at the position of R1and / or R9.
[0073] The term "halo-C1-10-alkyl" or "halo-C1-6-alkyl", respectively, means that one or more hydrogen atoms in the alkyl chain are replaced by a halogen, as defined below. A preferred example thereof is the formation of a -CF3 group.
[0074] "C2-10-alkenyl" means an alkyl chain having 2 to 10 carbon atoms which may be straight chained or branched, containing at least one carbon to carbon double bond. Examples thereof include ethenyl, propenyl, decenyl, 2-methylenehexyl and (2E,4E)-hexa-2,4-dienyl. Preferred is " C2-6-alkenyl".
[0075] "C2-10-alkynyl" means an alkyl chain having 2 to 10 carbon atoms which may be straight chained or branched, containing at least one carbon to carbon triple bond. Examples thereof include ethynyl, propynyl and decynyl. Preferred is " C2-6-alkynyl".
[0076] A “Co-w-alkylene” means that the respective group is divalent and connects the attached residue with the remaining part of the molecule. Moreover, in the context of the present invention, “Co-alkylene” is meant to represent a bond. Preferred is "C0-6-alkylene".
[0077] A C3-10-cycloalkyl group means a saturated or partially unsaturated mono-, bi-, spiro- or multicyclic ring system comprising 3 to 10 carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, bicyclo[2.2.2]octyl, bicyclo[2.2.1]heptyl, adamantyl and pentacyclo[4.2.0.02’5.03’8.04’7]octyl. Preferred is a C3-6-cycloalkyl group. More preferred is a cyclopropyl group.
[0078] A C3-10-heterocycloalkyl group means a saturated or partially unsaturated 3 to 10 membered carbon mono-, bi-, spiro- or multicyclic ring wherein 1, 2 or 3 carbon atoms are replaced by 1, 2 or 3 heteroatoms, respectively, wherein the heteroatoms are independently selected from N, O and S. Examples thereof include epoxidyl, oxetanyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl tetrahydropyranyl, 1,4-dioxanyl, morpholinyl, 4-quinuclidinyl, 1,4-dihydropyridinyl and 3,6-dihydro-2 / 7-thiopyranyl. The C3-10-heterocycloalkyl group can be connected via a carbon or nitrogen atom. Preferred is a C3-6-heterocycloalkyl group.
[0079] A 5- to 10-membered mono- or bicyclic heteroaromatic ring system (within the application also referred to as heteroaryl) containing up to 5 heteroatoms means a monocyclic heteroaromatic ring such as pyrrolyl, imidazolyl, furanyl, thiophenyl, pyridinyl, pyrimidinyl, pyrazinyl, pyrazolyl, oxazolyl, isoxazolyl, triazolyl, oxadiazolyl and thiadiazolyl. Preferred are 5- to 6-membered monocyclic heteroaromatic rings. It further means a bicyclic ring system wherein the heteroatom(s) may be present in one or both rings including the bridgehead atoms. Examples thereof include quinolinyl, isoquinolinyl, quinoxalinyl, benzimidazolyl, benzisoxazolyl, benzodioxanyl, benzofuranyl, benzoxazolyl, indolyl, indolizinyl and pyrazolo[1,5-a]pyrimidinyl. Incase of a bicyclic ring system one ring system can be partially unsaturated. Examples thereof include benzo[d][1,3]dioxolyl, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenzo[b]thiophenyl and indolinyl. The nitrogen or sulphur atom of the heteroaryl system may also be optionally oxidized to the corresponding / V-oxide, S-oxide or S, S-dioxide. If not stated otherwise, the heteroaryl system can be connected via a carbon or nitrogen atom. Examples for / V-linked heterocycles are
[0080]
[0081] A 6- to 10-membered mono- or bicyclic aromatic ring system (within the application also referred to as aryl) means an aromatic carbon cycle such as phenyl or naphthalenyl. Preferred is a 6-membered aromatic ring (phenyl).
[0082] The term " / V-oxide" denotes compounds, where the nitrogen in the heteroaromatic system (preferably pyridinyl) is oxidized. Such compounds can be obtained in a known manner by reacting a compound of the present invention (such as in a pyridinyl group) with H2O2 or a peracid in an inert solvent.
[0083] Halogen is selected from fluorine, chlorine, bromine and iodine, preferred are fluorine and chlorine.
[0084] Furthermore, the compounds of the present invention are partly subject to tautomerism. For example, if a heteroaromatic group containing a nitrogen atom in the ring is substituted with a hydroxy group on the carbon atom adjacent to the nitrogen atom, the following tautomerism can appear:
[0085]
[0086] A C3-10-cycloalkyl or C3-10-heterocycloalkyl group can be connected straight or spirocyclic, e.g. when cyclohexane is substituted with the heterocycloalkyl group oxetane, the following structures are possible:
[0087]
[0088] The term "1,4-orientation" denotes the specific relative position of the two substituents on the same ring and means that on a ring the substituents have at least one possibility, where 4 atoms are between the two substituents in the ring attached to the ring system, e.g.
[0089]
[0090] It will be appreciated by the skilled person that when lists of alternative substituents include members which, because of their valency requirements or other reasons, cannot be used to substitute a particular group, the list is intended to be read with the knowledge of the skilled person to include only those members of the list which are suitable for substituting the particular group.
[0091] The compounds according to the Formula (I) can also be present in the form of deuterated analogs and isotopic variants.
[0092] As defined in the international application W02022 / 090409 “deuteration”, “deuterium labelled”, “deuterium substituted" or “deuterated" means to replace hydrogen atom(s) of the compound of Formula (I) by deuterium (2H, represented by “D”). In deuterated analogs of the compounds of Formula (I), any hydrogen can be replaced by deuterium, preferably the residue R1represents CD3.
[0093] The compounds as defined by the Formula (I) also cover other “isotope variants”, i.e. compounds which may contain one or more other isotopically labeled atoms beside deuterium mentioned above. Examples of additional isotopes besides deuterium that can be incorporated into compounds of the disclosure include further isotopes of hydrogen (i.e. tritium or3H), as well as isotopes of carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as, but not limited to11C,13C,14C,15N,18F,19F,31P,32P,35P,35S,36CI and125l. The disclosure further comprises various isotopically labelled compounds into which radioactive isotopes such as3H,13C and14C are incorporated. Such isotopically labelled compounds may be useful in metabolic studies, reaction kinetic studies, detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays or radioactive treatment of patients.
[0094] As described in the international application W02022 / 090409 deuterated aminothiazole compounds (i.e. where any hydrogen is replaced by deuterium) were found to exhibit increased resistance to metabolism and were thus considered as useful for increasing the half-life of the compound of Formula (I), compared to a respective undeuterated compound, when administered to a mammal, e.g. a human. The concentration of deuterium may be defined by an isotopic enrichment factor. In the compounds of this disclosure any atom specifically designated as a deuterium (D) is meant to represent deuterium with an isotopic purity of at least 50%, preferably an isotopic purity of at least 95%, more preferably an isotopic purity of at least 99%. The percentage of deuterium incorporation can be obtained by quantitative analysis using a number of conventional methods, such as mass spectroscopy (peak area) or by quantifying the remaining residual1H-NMR signals of the specific deuteration site compared to signals from internal standards or other, non-deuterated1H signals in the compound. It will be recognized that some variation of natural isotopic abundance occurs in a synthesized compound depending upon the origin of chemical materials used in the synthesis. Thus, preparation of non-deuterated analogs of compounds of the present invention will inherently contain small amounts of deuterated isotopologues. The concentration of naturally abundant stable hydrogen and carbon isotopes, notwithstanding this variation, is small and immaterial as compared to the degree of stable isotopic substitution of compounds of this invention. The term “isotopic enrichment factor” at aparticular position normally occupied by hydrogen refers to the ratio between the abundance of deuterium at the position and the natural abundance of deuterium at that position. By way of example, an isotopic enrichment factor of 3500 means that the amount of deuterium at the particular position is 3500-fold the natural abundance of deuterium, or that 52.5% of the compounds have deuterium at the particular position (i.e., 52.5% deuterium incorporation at the given position). The abundance of deuterium in the oceans of Earth is approximately one atom in 6500 hydrogen atoms (about 154 parts per million (ppm)). Deuterium thus accounts for approximately 0.015 percent (on a weight basis, 0.030 percent) of all naturally occurring hydrogen atoms in the oceans on Earth; the abundance changes slightly from one kind of natural water to another.
[0095] If the compounds of this disclosure are present in the form of deuterated variants, they are preferably characterized by an isotopic enrichment factor of at least 6300, or by a deuteration degree of at least 95%. More preferably by an isotopic enrichment factor of at least 6500, or by a deuteration degree of at least 98%.
[0096] The compounds used in the present invention can be in the form of a pharmaceutically acceptable salt or a solvate, or both. The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids, including inorganic bases or acids and organic bases or acids. In case the compounds of the present invention contain one or more acidic or basic groups, the invention also comprises their corresponding pharmaceutically or toxicologically acceptable salts, in particular their pharmaceutically utilizable salts. Thus, the compounds of the present invention which contain acidic groups can be used according to the invention, for example, as alkali metal salts, alkaline earth metal salts or ammonium salts. More precise examples of such salts include sodium salts, potassium salts, calcium salts, magnesium salts or salts with ammonia or organic amines such as, for example, ethylamine, ethanolamine, triethanolamine or amino acids. The compounds of the present invention which contain one or more basic groups, i.e. groups which can be protonated, can be used according to the invention in the form of their addition salts with inorganic or organic acids. Examples of suitable acids include hydrogen chloride, hydrogen bromide, phosphoric acid, sulfuric acid, nitric acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acids, oxalic acid, acetic acid, tartaric acid, lactic acid, salicylic acid, benzoic acid, formic acid, propionic acid, pivalic acid, diethylacetic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, maleic acid, malic acid, sulfaminic acid, phenylpropionic acid, gluconic acid, ascorbic acid, isonicotinic acid, citric acid, adipic acid, and other acids known to the person skilled in the art. If the compounds of the present invention simultaneously contain acidic and basic groups in the molecule, the invention also includes, in addition to the salt forms mentioned, inner salts or betaines (zwitterions). The respective salts can be obtained by customary methods which are known to the person skilled in the art like, for example, by contacting these with an organic or inorganic acid or base in a solvent or dispersant, or by anion exchange or cation exchange with other salts. The present invention also includes all salts of the compounds of the present invention which, owing to low physiological compatibility, are not directly suitable for use in pharmaceuticals but which can be used, forexample, as intermediates for chemical reactions or for the preparation of pharmaceutically acceptable salts.
[0097] According to expert's knowledge the compounds of the invention as well as their salts may contain, e.g. when isolated in crystalline form, varying amounts of solvents. Included within the scope of the invention are therefore all solvates and in particular all hydrates of the compounds of Formula (I) or of Formula (II) as defined further below.
[0098] Depending on the substitution pattern, the compounds according to the invention can exist in stereoisomeric forms which either behave as image and mirror image (enantiomers), or which do not behave as image and mirror image (diastereomers). The invention relates both to the enantiomers or diastereomers and their respective mixtures. Like the diastereomers, the racemic forms can be separated into the stereoisomerically uniform components in a known manner.
[0099] The scope of the invention includes those compounds which are only converted into the actual active compounds of the Formulas (I) and (II) once inside the body (so-called prodrugs).
[0100] The invention relates in particular to the following embodiments:
[0101] A preferred embodiment of the invention relates to compounds of Formula (I) as defined above or of Formula (II) as defined below, wherein
[0102] X is selected from the group consisting of
[0103]
[0104] and wherein L, R1, R2, R3, R5, R6, R7, R8, R9, R11, R12, R13, n, x and y have the meaning as defined in any of the embodiments described herein.
[0105] A more preferred embodiment of the invention relates to compounds of Formula (I) as defined above or of Formula (II) as defined below, wherein
[0106]
[0107] and wherein L, R1, R2, R3, R5, R6, R7, R8, R9, R11, R12, R13, n, x and y have the meaning as defined in any of the embodiments described herein.
[0108] A further (similarly) more preferred embodiment of the invention relates to compounds of Formula (I) as defined above or of Formula (II) as defined below, wherein
[0109] QZNR8
[0110] X is R9,
[0111] and wherein L, R1, R2, R3, R5, R6, R7, R8, R9, R11, R12, R13, n, x and y have the meaning as defined in any of the embodiments described herein.It is further preferred that in any one of the embodiments disclosed herein in the compounds of Formula (I)
[0112] R5and R6are independently selected from H and Ci-3-alkyl;
[0113] R7is selected from a phenyl and 5- or 6-membered heteroaryl, wherein phenyl and heteroaryl are optionally substituted with 1 to 3 substituents independently selected from halogen, OH, Me (-CH3), -OMe (-O-CH3), -CHF2, -CF3, -OCHF2, -OCF3, and wherein the phenyl or 5- or 6-membered heteroaryl carries a 6- to 10-membered aryl or a 5- to 10-membered heteroaryl, wherein said 6- to 10-membered aryl or a 5- to 10-membered heteroaryl is optionally substituted with 1 to 5 substituents independently selected from halogen, -CN, - NO2, -OH, -R13, -OR13, -CO2R11, -NR11R12, -C(=O)R11, -C(=S)R11, -C(=O)NR11R12, - NR11C(=O)NR11R12, -NR11C(=O)OR13, -OC(=O)NR11R12, -C(=S)NR11R12, NR11C(=S)NR11R12, -NR11C(=S)OR13, -OC(=S)NR11R12; -SOy-C1-6-alkyl, -SOy-halo-Ci-6- alkyl, -SR11, -SOXR13, -SO3R11, -SO2NR11R12, -NR11SO2R13, -NR11SO2NR11R12;
[0114] and wherein the remaining substituents have the meaning as defined in any of the embodiments described herein.
[0115] With respect to such preferred selection it is more preferred that in any one of the embodiments disclosed herein in the compounds of Formula (I)
[0116] R5and R6are independently selected from H and Ci-3-alkyl;
[0117] R7is selected from a phenyl and 5- or 6-membered heteroaryl, wherein phenyl and heteroaryl are optionally substituted with 1 to 3 substituents independently selected from halogen, - OH, -Me (-CH3), -OMe (-O-CH3), -CHF2, -CF3, -OCHF2, -OCF3, and wherein the phenyl or 5- or 6-membered heteroaryl carries a phenyl or 5- to 6-membered heteroaryl, wherein said phenyl or 5- to 6-membered heteroaryl is optionally substituted with 1 to 5 substituents independently selected from halogen, -CN, -NO2, -OH, -R13, -OR13, -CO2R11, -NR11R12, - C(=O)R11, -C(=S)R11, -C(=O)NR11R12, -NR11C(=O)NR11R12, -NR11C(=O)OR13, - OC(=O)NR11R12, -C(=S)NR11R12, -NR11C(=S)NR11R12, -NR11C(=S)OR13, -OC(=S)NR11R12; - SOy-C1-6-alkyl, -SOy-halo-C1-6-alkyl, -SR11, -SOXR13, -SO3R11, -SO2NR11R12, -NR11SO2R13, - NR11SO2NR11R12;
[0118] and wherein the remaining substituents have the meaning as defined in any of the embodiments described herein.
[0119] Further, it is most preferred, that in any one of the embodiments disclosed herein R5and R6are hydrogen.
[0120] It is (similarly) most preferred, that in any one of the embodiments disclosed herein R7is phenyl which is optionally substituted with 1 to 3 substituents independently selected from halogen, -OH, -Me (-CH3), -OMe (-O-CH3), -CHF2, -CF3, -OCHF2, -OCF3 and wherein said phenyl carries a phenyl or 5- to 10-membered heteroaryl which may optionally be substituted with 1 to 5 substituents independently selected from halogen, -CN, -NO2, -OH, -R13, -OR13, -CO2R11, -NR11R12, -C(=O)R11, -C(=S)R11, -C(=O)NR11R12, -NR11C(=O)NR11R12, -NR11C(=O)OR13, -OC(=O)NR11R12, -C(=S)NR11R12, -NR11C(=S)NR11R12, -NR11C(=S)OR13, -OC(=S)NR11R12, -SOy-C1-6-alkyl, -SOy-halo-C1-6-alkyl, -SR11, -SOXR13, -SO3R11, -SO2NR11R12, -NR11SO2R13, -NR11SO2NR11R12.
[0121] It is (similarly) most preferred, that in any one of the embodiments disclosed herein R7is phenyl which is optionally substituted with 1 to 3 substituents independently selected from halogen, -OH, -Me (-CH3), -OMe (-O-CH3), -CHF2, -CF3, -OCHF2, -OCF3 and wherein said phenyl carries a phenyl or 5- to 6-membered heteroaryl which may optionally be substituted with 1 to 5 substituents independently selected from halogen, -CN, -NO2, -OH, -R13,- OR13, -CO2R11, -NR11R12, -C(=O)R11, -C(=S)R11, -C(=O)NR11R12, -NR11C(=O)NR11R12, -NR11C(=O)OR13, -OC(=O)NR11R12, -C(=S)NR11R12, -NR11C(=S)NR11R12, -NR11C(=S)OR13, -OC(=S)NR11R12; -SOy-C1-6-alkyl, -SOy-halo-C1-6-alkyl, -SR11, -SOxR13, -SO3R11, -SO2NR11R12, -NR11SO2R13, -NR11SO2NR11R12.
[0122] In an even more preferred embodiment in combination with any of the above or below embodiments R7is phenyl or thiophenyl, which is optionally substituted with 1 to 3 fluoro substituents and which carries a phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or 5- or 6-membered heteroaryl is optionally substituted with 1 to 5 substituents independently selected from halogen, -OH, -Me (-CH3), -OMe (-O-CH3), -CHF2, -CF3, -OCHF2, -OCF3.
[0123] In an even more preferred embodiment in combination with any of the above or below embodiments R7is phenyl which is optionally substituted with 1 to 3 fluoro substituents and which carries a phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or 5- or 6-membered heteroaryl is optionally substituted with 1 to 5 substituents independently selected from halogen, -OH, -Me (-CH3), -OMe (-O-CH3), -CHF2, -CF3, -OCHF2, -OCF3.
[0124] In an even more preferred embodiment in combination with any of the above or below embodiments R7is phenyl which carries in 1,4-orientation a phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or 5- or 6-membered heteroaryl is optionally substituted with 1 to 5 substituents independently selected from F, Cl, -OH, -Me (-CH3), -OMe (-O-CH3), -CHF2, -CF3, -OCHF2, -OCF3.
[0125] In an even more preferred embodiment in combination with any of the above or below
[0126] embodiments R7is selected from
[0127]
[0128] , and carries a phenyl, wherein said phenyl is optionally substituted with 1 to 5 substituents independently selected from -D, halogen, -OH, -Me (-CH3), cyclopropyl, formyl, acetyl, -OMe (-O-CH3), -O-CD3, -CHF2, -CF3, -OCHF2, -OCF3 and ethynyl.
[0129] In an even more preferred embodiment in combination with any of the above or below
[0130] embodiments R7is selected from
[0131]
[0132] and carries a phenyl, wherein saidphenyl is optionally substituted with 1 to 5 substituents independently selected from -D, fluoro, chloro, cyclopropyl, formyl, acetyl, -OMe (-O-CH3), -O-CD3, -CHF2 and ethynyl.
[0133] Particularly preferred are compounds of Formula (I) as defined in any of the embodiments above or below, wherein R7is phenyl, substituted with 1 to 4 substituents (Rx), wherein the 1 to 4 substituents Rxmay independently have the meaning as defined above for the possible substituents of R7and which is represented by Formula (II)
[0134]
[0135] Particularly, in the Formula (II) the 1 to 4, preferably 1 to 3, substituents Rxcan be defined as follows:
[0136] Rxcan independently be selected from halogen, -CN, -NO2, -OH, -Ci-6-alkyl, -O-Ci-6-alkyl, -C3-6-cycloalkyl, -O-C3-6-cycloalkyl, -C3-6-heterocycloalkyl, -O-C3-6-heterocycloalkyl, -SOy-Ci-6-alkyl, -CO2H, -C(=O)O-Ci-6-alkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -O-(6-to 10-membered aryl) and -O-(5- to 10-membered heteroaryl), wherein
[0137] alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with 1 to 5 substituents independently selected from halogen, -CN, -NO2, -OH, -R13, -OR13, - CO2R11, -NR11R12, -C(=O)R11, -C(=S)R11, -C(=O)NR11R12, -NR11C(=O)NR11R12, - NR11C(=O)OR13, -OC(=O)NR11R12, -C(=S)NR11R12, -NR11C(=S)NR11R12, NR11C(=S)OR13, -OC(=S)NR11R12; -SOy-C1-6-alkyl, -SOy-halo-C1-6-alkyl, -SR11, -SOXR13, -SO3R11, -SO2NR11R12, -NR11SO2R13, -NR11SO2NR11R12.
[0138] Preferably Rxcan independently be selected from halogen, -OH, -Me (-CH3), -OMe (-0-CH3), -CHF2, -CF3, -OCHF2, -OCF3, and carries a 6- to 10-membered aryl ora 5- to 10-membered heteroaryl, wherein said 6- to 10-membered aryl or a 5- to 10-membered heteroaryl is optionally substituted with 1 to 5 substituents independently selected from halogen, -CN, -NO2, -OH, -R13, -OR13, -CO2R11, -NR11R12, -C(=O)R11, -C(=S)R11, -C(=O)NR11R12, -NR11C(=O)NR11R12, -NR11C(=O)OR13, -OC(=O)NR11R12, -C(=S)NR11R12, -NR11C(=S)NR11R12, -NR11C(=S)OR13, -OC(=S)NR11R12; -SOy-C1-6-alkyl, -SOy-halo-C1-6-alkyl, -SR11, -SOXR13, -SO3R11, -SO2NR11R12, -NR11SO2R13, -NR11SO2NR11R12.
[0139] Preferably Rxcan independently be selected from halogen, -OH, -Me (-CH3), -OMe (-0-CH3), -CHF2, -CF3, -OCHF2, -OCF3, and carries a phenyl or 5- to 6-membered heteroaryl, wherein said phenyl or 5- to 6-membered heteroaryl is optionally substituted with 1 to 5 substituents independently selected from halogen, -CN, -NO2, -OH, -R13, -OR13, -CO2R11, -NR11R12, -C(=O)R11, -C(=S)R11, -C(=O)NR11R12, -NR11C(=O)NR11R12, -NR11C(=O)OR13, -OC(=O)NR11R12, -C(=S)NR11R12, -NR11C(=S)NR11R12, -NR11C(=S)OR13, -OC(=S)NR11R12; -SOy-C1-6-alkyl, -SOy-halo-Ci-6-alkyl, -SR11, -SOXR13, -SO3R11, -SO2NR11R12, -NR11SO2R13, -NR11SO2NR11R12;
[0140] Preferably Rxcan independently be selected from halogen, -OH, -Me (-CH3), -OMe (-0-CH3), -CHF2, -CF3, -OCHF2, -OCF3 and carries a phenyl or 5- to 6-membered heteroaryl which may optionally be substituted with 1 to 5 substituents independently selected from halogen, -CN, -NO2, -OH, -R13, -OR13, -CO2R11, -NR11R12, -C(=O)R11, -C(=S)R11, -C(=O)NR11R12, -NR11C(=O)NR11R12, -NR11C(=O)OR13, -OC(=O)NR11R12, -C(=S)NR11R12, -NR11C(=S)NR11R12, -NR11C(=S)OR13, -OC(=S)NR11R12; -SOy-C1-6-alkyl, -SOy-halo-C1-6-alkyl, -SR11, -SOXR13, -SO3R11, -SO2NR11R12, -NR11SO2R13, -NR11SO2NR11R12.
[0141] More preferably Rxcan independently be selected from fluoro substituents and carries a phenyl or 5- or 6-membered heteroaryl, wherein said phenyl or 5- or 6-membered heteroaryl is optionally substituted with 1 to 5 substituents independently selected from halogen, -OH, -Me (-CH3), -OMe (-O-CH3), -CHF2, -CF3, -OCHF2, -OCF3.
[0142] Even more preferably one Rxsubstituent is present and represents phenyl or 5- or 6-membered heteroaryl bound in 1,4-orientation, which is optionally substituted with 1 to 5 substituents independently selected from F, Cl, -OH, -Me (-CH3), -OMe (-O-CH3), -CHF2, -CF3, -OCHF2, -OCF3.
[0143]
[0144] In a further embodiment in combination with any of the above or below embodiments R7ted from the following groups
[0145]
[0146] In a further embodiment in combination with any of the above or below embodiments R7ted from the following groups
[0147]
[0148] In a further embodiment in combination with any of the above or below embodiments R7ted from the following groups
[0149]
[0150] In yet another preferred embodiment in combination with any of the above or below embodiments in Formula (I) and Formula (II) in the group
[0151]
[0152] represents 0.
[0153] In yet another alternative preferred embodiment in combination with any of the above or below embodiments in Formula (I) and Formula (II) in the group
[0154]
[0155] n” represents 0 and R7is selected from the groups defined above, i.e. R7is selected from the following groups
[0156]
[0157]
[0158] In yet another alternative preferred embodiment in combination with any of the above or below embodiments in Formula (I) and Formula (II) in the group
[0159]
[0160] “n” represents 0 and R7is selected from the following groups
[0161]
[0162] In yet another alternative preferred embodiment in combination with any of the above or below embodiments in Formula (I) or (II) the group
[0163] X is selected from a group consisting of
[0164]
[0165] R1is independently selected from H, halogen, -Ci-6-alkyl, halo-Ci-6-alkyl, -C3-6-cycloalkyl, halo-Cs-6-cycloalkyl, -O-Ci-6-alkyl, -O-halo-Ci-6-alkyl and -NH-Ci-6-alkyl;
[0166] preferably R1is independently selected from -C1-3-alkyl, halo-C1-3-alkyl and cyclopropyl, more preferably R1is -Me (-CH3).
[0167] In yet another alternative preferred embodiment in combination with any of the above or below embodiments in Formula (I) or (II) the group
[0168] X is selected from a group consisting of
[0169]
[0170] R1is independently selected from H, halogen, -C1-6-alkyl, halo-Ci-6-alkyl, -C3-6-cycloalkyl, halo-Cs-6-cycloalkyl, -O-Ci-6-alkyl, -O-halo-Ci-6-alkyl and -NH-Ci-6-alkyl;
[0171] preferably R1is independently selected from -C1-3-alkyl, halo-C1-3-alkyl and cyclopropyl, more preferably R1is -Me (-CH3).
[0172] In yet another alternative preferred embodiment in combination with any of the above or below embodiments in Formula (I) or (II) the group
[0173]
[0174] R1is independently selected from -C1-3-alkyl, halo-C1-3-alkyl and cyclopropyl, more preferably R1is -Me (-CH3).
[0175] In yet another alternative preferred embodiment in combination with any of the above or below embodiments R2and R3are independently selected from H, -C1-3-alkyl, halo-C1-3-alkyl, -O-Ci-3-alkyl, -O-fluoro-Ci-3-alkyl, -C3-6-cycloalkyl and -C3-6-heterocycloalkyl, wherein alkyl, cycloalkyl and heterocycloalkyl are optionally substituted with 1 to 5 substituents independently selected from F, Cl, -OH, oxo, -Me (-CH3), -CHF2and -CF3;
[0176] or R2and R3when taken together with the nitrogen to which they are attached complete a 5- to 6-membered ring containing carbon atoms and optionally containing one heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of F, Cl, -OH, oxo, -Me (-CH3), -CHF2 and -CF3; R8is selected from H, -CN, -NO2, -OH, -C1-3-alkyl, -O-C1-3-alkyl, fluoro-C1-3-alkyl and -O-fluoro-C1-3-alkyl; and
[0177] R9is selected from -Ci-3-alkyl, t-butyl, fluoro-Ci-3-alkyl, cyclopropyl, fluoro-Ci-3-alkyl-cyclopropyl, -C3-10-heterocycloalkyl.
[0178] In yet another alternative preferred embodiment in combination with any of the above or below embodiments R2, R3and R8are H;
[0179] In yet another alternative preferred embodiment in combination with any of the above or below embodiments R9is selected from -Ci-3-alkyl, t-butyl, fluoro-Ci-3-alkyl, cyclopropyl, fluoro-Ci-3-alkyl-cyclopropyl, -C3-10-heterocycloalkyl.
[0180] In yet another alternative preferred embodiment in combination with any of the above or below embodiments R9is methyl.
[0181] According to the present invention in Formula (I) and Formula (II) the groupo
[0182]
[0183] represents a central saturated or partially saturated C4-io-membered heterocycloalkyl-ring or a 6-membered heteroaryl-ring, said central ring being characterized by the ring-forming group [*-C-C(=O)-N-*], wherein “*” indicates the binding positions within the molecule. Accordingly, for clarification, such central ring “L” is mandatorily bound to the group
[0184]
[0185] via a ring-carbon atom. Although the ring “L” may contain 1 or 2 additional heteroatoms independently selected from O, S and N, such additional heteroatom cannot replace the ring-carbon atom on the binding position to the group carrying R7.
[0186] In a preferred embodiment, in combination with any of the embodiments described above or below, the central ring “L” does not contain an oxygen (O) as an additional heteroatom. In an alternative preferred embodiment, in combination with any of the embodiments described above or below, the central ring “L” does not contain any additional heteroatom.
[0187] Furthermore, in a preferred embodiment, in combination with any of the embodiments described above or below, the central ring “L” does not carry a hydroxy group (-OH) as an additional substituent. In an alternative preferred embodiment, in combination with any of the embodiments described above or below, the central ring “L” does not carry any additional subtituent.
[0188] In one aspect of the invention in any of the above or below described embodiments in Formula (I) and Formula (II) the group
[0189]
[0190] is selected from the following groups
[0191]
[0192] In another aspect of the invention in any of the above or below described embodiments in Formula (I) and Formula (II) the group
[0193]
[0194] is selected from the following groups
[0195]
[0196] In another aspect of the invention in any of the above or below described embodiments in Formula (I) and Formula (II) the group
[0197]
[0198] In another aspect of the invention in any of the above or below described embodiments in Formula (I) and Formula (II) the group
[0199]
[0200] In another aspect of the invention in any of the above or below described embodiments in Formula (I) and Formula (II) the group
[0201]
[0202] In yet another alternative preferred embodiment in combination with any of the above or below embodiments in Formula (I) and Formula (II)
[0203] R2and R3are independently selected from H, -C1-3-alkyl, halo-C1-3-alkyl, -O-Ci-3-alkyl, -O-fluoro- Ci-3-alkyl, -C3-6-cycloalkyl and -C3-6-heterocycloalkyl, wherein alkyl, cycloalkyl and heterocycloalkyl are optionally substituted with 1 to 5 substituents independently selected from F, Cl, -OH, oxo, -Me (-CH3), -CHF2and -CF3;
[0204] or R2and R3when taken together with the nitrogen to which they are attached complete a 5- to 6-membered ring containing carbon atoms and optionally containing one heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of F, Cl, -OH, oxo, -Me (- CH3), -CHF2and -CF3;
[0205] R8is selected from H, -CN, -NO2, -OH, -Ci-3-alkyl, -O-Ci-3-alkyl, fluoro-Ci-3-alkyl and -O-fluoro- Ci-3-alkyl,
[0206] R9is selected from -Ci-3-alkyl, t-butyl, fluoro-Ci-3-alkyl and -cyclopropyl.
[0207] In a further embodiment in Formula (I) and Formula (II) the group
[0208]
[0209] R7is selected from the following groups
[0210]
[0211]
[0212] R7is selected from the following groups
[0213]
[0214] In a further embodiment in Formula (I) and Formula (II) the group
[0215]
[0216] R7is selected from the following groups
[0217]
[0218] In a further embodiment in Formula (I) and Formula (II) the group
[0219]
[0220] R7is selected from the following groups
[0221]
[0222] In a further embodiment in Formula (I) and Formula (II) the group
[0223] t
[0224]
[0225] In a further embodiment in Formula (I) and Formula (II) the group
[0226] t
[0227]
[0228] R7is selected from the following groups
[0229]
[0230]
[0231] In a further embodiment in Formula (I) and Formula (II) the group
[0232]
[0233] R7is selected from the following groups
[0234]
[0235] In a further embodiment in Formula (I) and Formula (II) the group
[0236] t
[0237]
[0238] R7is selected from the following groups
[0239]
[0240] In a further embodiment in Formula (I) and Formula (II) the group
[0241] t
[0242]
[0243] R7is selected from the following groups
[0244]
[0245] In a further embodiment in Formula (I) and Formula (II) the group
[0246] t
[0247]
[0248] R7is selected from the following groups
[0249]
[0250] In such embodiments it is further preferred that in the group
[0251]
[0252] represents 0.
[0253] Further, in any of the above or below described embodiments the substituents may individually or in any combination with each other have the following meaning:
[0254] R2and R3may independently be selected from H, -Me (-CH3), -Et (-CH2-CH3), -CH2CH2OH and -CH2CH2F.
[0255] R2and R3may be H.
[0256] R8may be selected from H, -CN, -NO2, -OH, -C1-3-alkyl, -O-C1-3-alkyl, fluoro-C1-3-alkyl and -O-fluoro-C1-3-alkyl.
[0257] R8may be selected from H, -CN, -NO2, -OH, -Me (-CH3), -Et (-CH2-CH3), -OMe (-O-CH3) and -OEt (-O-CH2-CH3).
[0258] R8may be selected from H and -CN.
[0259] R8may be H.
[0260] R9may be selected from -Ci-3-alkyl, fluoro-Ci-3-alkyl, cyclopropyl and -C3-10-heterocycloalkyl. R9may be selected from -Me (-CH3), -Et (-CH2-CH3), -CHF2, -CF3, cyclopropyl and oxetane. R9may be selected from -Me (-CH3), -Et (-CH2-CH3) and cyclopropyl.
[0261] R9may be -Me (-CH3) or cyclopropyl.
[0262] R9may be -Me (-CH3).
[0263] R11and R12may independently be selected from H, -Me (-CH3) and -Et (-CH2-CH3).
[0264] R11and R12may be H.R13may be selected from -C1-3-alkyl, fluoro-C1-3-alkyl, -C2-3-alkynyl, cyclopropyl and -C3-10-heterocycloalkyl.
[0265] R13may be selected from -C1-3-alkyl, fluoro-C1-3-alkyl, cyclopropyl and -C3-10-heterocycloalkyl. R13may be selected from -Me (-CH3), -CD3, -Et (-CH2-CH3), -CHF2, -CF3, ethynyl, cyclopropyl and oxetane.
[0266] R13may be selected from -Me (-CH3), -Et (-CH2-CH3), -CHF2, -CF3, cyclopropyl and oxetane. R13may be -Me (-CH3), -CD3, ethynyl or cyclopropyl.
[0267] R13may be -Me (-CH3) or cyclopropyl.
[0268] R13may be -Me (-CH3)
[0269] R13may be -CD3.
[0270] R13may be ethynyl.
[0271] R13may be cyclopropyl.
[0272] In yet another alternative preferred embodiment in combination with any of the above or below embodiments n is selected from 0 and 1, preferably n is 0.
[0273] Particularly preferred compounds of the present invention are represented by the following formulas:
[0274]
[0275] or an enantiomer, diastereomer, tautomer, isotopic variant, / V-oxide, solvate and pharmaceutically acceptable salt thereof.
[0276] Further particularly preferred compounds of the present invention are represented by the following enantiomers of compounds shown above:
[0277]
[0278] Further preferred compounds of the present invention are represented by the following formulas:
[0279]
[0280]
[0281] or an enantiomer, diastereomer, tautomer, isotopic variant, / V-oxide, solvate and pharmaceutically acceptable salt thereof.
[0282] Further preferred compounds of the present invention are represented by the following enantiomers of compounds shown above:
[0283]
[0284]
[0285]
[0286] The compounds described anywhere herein can be prepared by the methods described in detail further below.
[0287] A further aspect of the present invention relates to the compounds of any of the abovedescribed embodiments for the use as a medicament.
[0288] Particularly the invention relates to the described compounds for use in the treatment or prophylaxis of a disease or disorder associated with viral infections.
[0289] More particularly the invention relates to the described compounds for use in the treatment or prophylaxis of a disease or disorder, which is associated with viral infections caused by herpes viruses, such as in particular by Herpes simplex viruses.
[0290] In a further aspect the invention relates to the described compounds for use in the treatment or prophylaxis of neurodegenerative diseases caused by viruses, particularly caused by herpes viruses such as Herpes simplex viruses, wherein such neurodegenerative diseases are in particular Alzheimer’s disease.
[0291] In a further aspect the inventions relates to the described compounds for the use in the treatment and prophylaxis of herpes infections, in particular Herpes simplex infections in patients displaying Herpes labialis, Herpes genitalis and Herpes- related keratitis, Herpetic esophagitis, Herpetic pneumonia, viral meningitis (e.g. Mollaret's meningitis), Alzheimer’s disease, encephalitis, or hepatitis; in patients with a suppressed immune system, such as AIDS patients, cancer patients, patients having a genetic immunodeficiency, transplant patients; in new-born children and infants; in Herpes-positive patients, in particular Herpes-simplex-positive patients, for suppressing recurrence or viral shedding (suppression therapy); in patients, in particular in Herpes-positive patients, in particular Herpes-simplex-positive patients, who are resistant to nucleosidic antiviral therapy such as acyclovir, penciclovir, famciclovir, ganciclovir, valacyclovir and / or compounds such as the phosphonates foscarnet or cidofovir.
[0292] In a further aspect the invention relates to the described compounds, which are characterized by an IC50 value (HSV-1 / Vero) in an in vitro activity selectivity assay HSV-1 on Vero cells as described in the Examples of the present invention of preferably IC50below 100 μM, more preferably IC50below 10 μM and very particularly perferable IC50below 1 μM.In a further aspect the invention relates to the described compounds, which are characterized by an ED50 value in an in vivo animal model as described in the Examples of the present invention preferably of ED50of less than 10 mg / kg for HSV-1, more preferably of less than 5 mg / kg for HSV-1, and very particularly preferably of less than 2 mg / kg for HSV-1.
[0293] The compounds according to the present invention are considered for the use in the prophylaxis and treatment of the respective disorders and diseases in humans as well as in animals, preferably in humans.
[0294] Accordingly, the invention relates to the use of the compounds as described herein for the preparation of a medicament.
[0295] Further, the invention relates to a method of treating a disease or disorder associated with viral infections, such as a disease or disorder, which is associated with viral infections caused by herpes viruses, such as in particular by Herpes simplex viruses as well as a method of treating neurodegenerative diseases caused by viruses, particularly caused by herpes viruses such as Herpes simplex viruses, wherein such neurodegenerative diseases are in particular Alzheimer's disease, said methods comprising administering to a human or animal in need thereof an effective amount of a compound or of a composition comprising said compounds as described herein.
[0296] Any suitable route of administration may be employed for providing a mammal, especially a human, with an effective dose of a compound of the present invention. For example, oral, rectal, topical, parenteral (including intravenous), ocular, pulmonary, nasal, and the like may be employed. Dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, creams, ointments, aerosols, and the like. Preferably compounds of the present invention are administered orally or as eye drops, more preferably the compounds of the present invention are administered orally.
[0297] In practical use, the compounds used in the present invention can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques. The carrier may take a wide variety of forms depending on the form of preparation desired for administration, e.g., oral or parenteral (including intravenous). In preparing the compositions for oral dosage form, any of the usual pharmaceutical media, auxiliaries, adjuvants or excipients may be employed and selected by a skilled person in accordance with the intended dosage form, such as for oral liquid preparations like suspensions, elixirs, solutions or drops, or for oral solid preparations like powders, hard and soft capsules, tablets, minitablets and granules or for dosage forms that can be administered intranasally like liquid drops or spray, including eye drops and nasal sprays. Among the available dosage forms, solid oral preparations are preferred over liquid preparations.
[0298] Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are obviously employed. If desired, tablets may be coated by standard aqueous or non-aqueous techniques. Such compositions and preparations should contain at least 0.1 percent of active compound. The percentage of active compound in these compositions may, of course, be varied and may conveniently be between about 2 percent to about 60 percent of the weight of the unit. The amountof active compound in such therapeutically useful compositions is such that an effective dosage will be obtained.
[0299] The effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration, the condition being treated and the severity of the condition being treated. Such dosage may be ascertained readily by a person skilled in the art.
[0300] The compounds of the present invention may also be present in combination with further active ingredients, in particular with one or more active ingredients exhibiting advantageous effects in the treatment of any of the disorders or diseases as described herein. Very particularly the compounds of the present invention are present in a composition in combination with at least one further active substance being effective in treating a disease or disorder associated with viral infections (antiviral active compounds), preferably a disease or disorder being associated with viral infections caused by herpes viruses, such as in particular by Herpes simplex viruses, thus relating to a so-called combination therapy. The at least one further active substance being effective in treating a disease or disorder associated with viral infections (antiviral active compounds) are preferably selected from the group consisting of nucleosidic drugs such as acyclovir, valacyclovir, penciclovir, ganciclovir, famciclovir and trifluridine, as well as compounds such as foscarnet and cidofovir.
[0301] Accordingly, the present invention further relates to a pharmaceutical composition comprising one or more of the compounds as described herein and at least one pharmaceutically acceptable carrier and / or excipient and / or at least one further active substance being effective in treating a disease or disorder associated with viral infections (antiviral active compounds).
[0302] EXPERIMENTAL PART
[0303] The compounds of the present invention can be prepared by a combination of methods known in the art.
[0304] Abbreviations
[0305] aq. aqueous
[0306] dba dibenzylidenaceton
[0307] DCM dichloromethane
[0308] DMSO dimethylsulfoxide
[0309] dppf 1,1 '-bis(diphenylphosphino)ferrocene
[0310] EA ethyl acetate
[0311] ESI electrospray ionization
[0312] I PA isopropylalcohol
[0313] LiHMDS lithium bis(trimethylsilyl)amide
[0314] LCMS liquid chromatography–mass spectrometry
[0315] PE petroleum ether
[0316] rt room temperaturesat. saturated
[0317] SFC supercritical fluid chromatography
[0318] TEA triethylamine
[0319] TFA trifluoroacetic acid
[0320] THF tetrahydrofuran
[0321] XantPhos (9,9-dimethyl-9 / 7-xanthene-4,5-diyl)bis(diphenylphosphane)
[0322] Experimental Section
[0323] Example 1: 2-(3-(2,,5,-Difluoro-[1,1,-biphenyl]-4-yl)-2-oxopiperidin-1-yl)-4-methylthiazole- 5-sulfonamide
[0324]
[0325] Step 1: 2-Chloro- / V, / V-bis(4-methoxybenzyl)-4-methylthiazole-5-sulfonamide (P1a)
[0326]
[0327] A suspension of 2-chloro-4-methylthiazole-5-sulfonyl chloride (5.0 g), TEA (4.4 g) and bis(4-methoxybenzyl)amine (5.5 g) in DCM (50 mL) was stirred at 0°C for 2 h, concentrated and purified by column chromatography (PE / EA = 83:17) to give compound P1a as a yellow solid, m / z 453.1 (M+H)+.
[0328] Step 2: Methyl 2-(2',5'-difluoro- biphenyl1-4-yl)acetate (P1b)
[0329]
[0330] P1b
[0331]
[0332] To a suspension of (2,5-difluorophenyl)boronic acid (16.5 g) and methyl 2-(4-bromophenyl)acetate (20 g) in 1,4-dioxane (300 mL) and H2O (40 mL) under N2 was added at 0°C Pd(dppf)Cl₂ (3.1 g) and Na₂CO₃ (34 g). The mixture was allowed to reach rt and stirred 1 h under N2, concentrated and purified by column chromatography (PE / EA = 95:5) to give compound P1b as a yellow oil. LCMS (ESI): m / z 263.2 (M+H)+.Step 3: Methyl 5-((tert-butoxycarbonyl)amino)-2-(2',5'-difluoro-[1,1'-biphenyl]-4-yl)pentanoate (P1c
[0333]
[0334]
[0335] To a solution of compound P1b (3.3 g) in anhydrous DMSO (60 mL) was added NaH (0.55 g, 60%) at 0°C and the mixture was stirred at 0°C for 0.5 h, then tert-butyl (3-bromopropyl)carbamate (2.7 g) was added and the mixture was stirred at 50°C for 1 h, carefully quenched with ice-water (50 mL) and extracted with EA (3 x 60 mL). The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂SO₄, filtered, concentrated and purified by column chromatography (PE / EA = 87:13) to give compound P1c as a colorless oil. LCMS (ESI): m / z 320.3 (M-100)+.
[0336] Step 4: Methyl 5-amino-2-(2',5'-difluoro- biphenyl1-4-yl)pentanoate (P1d)
[0337]
[0338]
[0339] To a solution of compound P1c (3.5 g) in EA (60 mL) was added HCI (4.0M in EA, 15 mL) at 0°C. The mixture was stirred at 25°C for 1 h and concentrated in vacuo to give compound P1d as a white solid, which was used in the next step without further purification. LCMS (ESI): m / z 320.3 (M+H)+.
[0340] Step 5: 3-(2',5'-Difluoro-[1,1'-biphenyl]-4-yl)piperidin-2-one (P1e)
[0341] P1e
[0342]
[0343] A suspension of compound P1d (3.0 g) and K₂CO₃ (3.9 g) in EtOH (40 mL) was stirred at 80°C for 2 h., cooled to rt, concentrated and purified by column chromatography (DCM / MeOH = 94:6) to give compound P1e as a white solid. LCMS (ESI): m / z 288.3 (M+H)+.Step 6: 2-(3-(2',5'-Difluoro-[1,1'-biphenyl]-4-yl)-2-oxopiperidin-1-yl)-N,N-bis(4-methoxybenzyl)-4-methylthiazole-5-sulfonamide (P1f)
[0344]
[0345] To a suspension of compound P1a (1.0 g) and compound P1e (0.66 g) in 1,4-dioxane (40 mL) was added XantPhos (0.13 g), Pd₂(dba)₃ (0.20 g) and Cs₂CO₃ (1.8 g) at 0°C under N2 and then the mixture was stirred at 100°C for 1 h under N2, cooled to rt, concentrated and purified by column chromatography (PE / EA = 7:3) to give compound P1f as a yellow solid. LCMS (ESI): m / z 704.0 (M+H)+.
[0346] Step 7: 2-(3-(2',5'-Difluoro-[1,1'-biphenyl]-4-yl)-2-oxopiperidin-1-yl)-4-methylthiazole-5-sulfonamide (1)
[0347] To compound P1f (1.5 g) was added TFA (20 mL) at 0°C. The mixture was stirred at 60°C for 3 h under N2, concentrated and purified by reversed-phase flash chromatography (C18) (0.1% NH4HCO3 in water, 10 to 80% MeCN) to give compound 1 as a white solid. LCMS (ESI): m / z 464.1 (M+H)+.
[0348] Separation of Enantiomers of Example 1:
[0349] Example 1A: (+)-2-(3-(2',5'-Difluoro-[1,1'-biphenyl]-4-yl)-2-oxopiperidin-1-yl)-4-methyl-thiazole-5-sulfonamide
[0350]
[0351] bitrarily assigned The title compound was prepared and further characterized by separation of the racemic mixture 1 by chiral SFC chromatography, using as stationary phase OJ 25×250 mm, 10 μm (Regis) and as mobile phase 40 / 60 vol.% CO₂ / MeOH.
[0352] The following conditions were applied:
[0353] Instrument: SFC- 150 (Waters)
[0354] Column temperature: rt
[0355] Flow rate: 120 mL / min
[0356] Back pressure: 100 bar
[0357] Detection wavelength: 214 nm
[0358] Cycle time: 5.6 minSample solution: 200 mg dissolved in 300 mL MeOH and DCM
[0359] Injection volume: 4.8 mL
[0360] Example 1A is the first eluting enantiomer with an enantiomeric excess (ee) of 99.4%. It has a positive specific optical rotation at [α]25589 nmin DCM.1H-NMR (400 MHz, CDCl₃) 67.53 (d, J = 7.2 Hz, 2H), 7.29 (d, J = 8.4 Hz, 2H), 7.15-7.07 (m, 2H), 7.03-6.96 (m, 1H), 4.99 (s, 2H), 4.44-4.38 (m, 1H), 4.22-4.15 (m, 1H), 4.00-3.96 (m, 1H), 2.62 (s, 3H), 2.39-2.33 (m, 1H), 2.26-2.04 (m, 3H). LCMS (ESI): m / z 464.1 (M+H)+.
[0361] Example 1B: (-)-2-(3-(2',5'-Difluoro-[1,1'-biphenyl]-4-yl)-2-oxopiperidin-1-yl)-4-methyl-thiazole-5-sulfonamide
[0362]
[0363] rbitrarily assigned The title compound was prepared and further characterized by separation of the racemic mixture 1 as described for Example 1A. Example 1B is the second eluting enantiomer with an ee of 99.6%. It has a negative specific optical rotation at [α]25589 nmin DCM.1H-NMR (400 MHz, CDCl₃) 57.53 (d, J = 6.8 Hz, 2H), 7.29 (d, J = 8.0 Hz, 2H), 7.16-7.07 (m, 2H), 7.03-6.97 (m, 1H), 4.97 (s, 2H), 4.45-4.38 (m, 1H), 4.22-4.15 (m, 1H), 4.00-3.96 (m, 1H), 2.62 (s, 3H), 2.38-2.34 (m, 1H), 2.27-2.05 (m, 3H). LCMS (ESI): m / z 464.1 (M+H)+.
[0364] Example 2: 2-(3-(2',5'-Difluoro-[1,1'-biphenyl]-4-yl)-2-oxopyrrolidin-1-yl)-4-methylthiazole-5-sulfonamide
[0365]
[0366] Step 1: Methyl 3-cyano-2-(2',5'-difluoro-[1,1'-biphenyl]-4-yl)propanoate (P2a)
[0367]
[0368]
[0369] To a solution of P1b (5.0 g) in THF (40 mL) was added lithium diisopropylamide (2M in THF, 10 mL) dropwise at -78°C and the mixture was stirred at -78°C for 30 min. 2-bromoacetonitrile (2.3 g) was added and the mixture was stirred at -78°C for 1 h. On completion, diluted with a sat. NH4CI solution (60 mL) and extracted with EA (3 x 60 mL). The combined organic layer was washed with brine (80 mL), dried over anhydrous Na₂SO₄, filtered, concentratedand purified by column chromatography (PE / EA = 4:1) to give compound P2a as a white solid. LCMS (ESI): m / z 302.2 (M+H)+.
[0370]
[0371] To a suspension of compound P2a (2.7 g) in MeOH was added ammonia (7M in MeOH, 30 mL) and Raney-Ni (52 mg). The mixture was stirred at rt for 2 h under a balloon filled with H2, filtered concentrated and purified by reversed-phase flash chromatography (C18) (0.1% NH4HCO3 in water, 10 to 60% MeCN) to give compound P2b as a white solid. LCMS (ESI): m / z 274.2 (M+H)+.
[0372] Step 3: 2-(3-(2',5'-Difluoro-[1,1'-biphenyl]-4-yl)-2-oxopyrrolidin-1-yl)-N,N-bis(4-methoxybenzyl)-4-methylthiazole-5-sulfonamide (P2c)
[0373]
[0374] To a suspension of compound P2b (0.4400 mg) and P1a (0.66 g, 1.47 mmol) 1,4-dioxane (15 mL) was added XantPhos (85 mg), Pd₂(dba)₃ (0.13 g) and Cs₂CO₃ (1.2 g) at 0°C under N2 and then the mixture was stirred at 100°C for 1 h under N2, cooled to rt, concentrated and purified by column chromatography (PE / EA = 64:36) to give compound P2c as a yellow solid. LCMS (ESI): m / z 690.2 (M+H)+.
[0375] Step 4: 2-(3-(2',5'-difluoro-[1,1'-biphenyl]-4-yl)-2-
[0376]
[0377] in-1-yl)-4-methylthiazole-5-sulfonamide (2)
[0378] To compound P2c (0.90 g) was added TFA (10 mL) at 0°C. The mixture was stirred at 60°C for 3 h under N2, concentrated and purified by reversed-phase flash chromatography (C18) (0.1% NH4HCO3 in water, 10 to 80% MeCN) to give compound 2 as a white solid. LCMS (ESI): m / z 450.1 (M+H)+.Separation of Enantiomers of Example 2:
[0379] Example 2A: (–)-2-(3-(2',5'-difluoro-[1,1'-biphenyl]-4-yl)-2-oxopyrrolidin-1-yl)-4-methylthiazole-5-sulfonamide
[0380] bitrarily assigned
[0381]
[0382] The title compound was prepared and further characterized by separation of the racemic mixture 2 by chiral SFC chromatography, using as stationary phase (R,R) Whelk-O® 1 25×250 mm, 10 μm (Regis) and as mobile phase 40 / 60 vol.% CO₂ / MeOH.
[0383] The following conditions were applied:
[0384] Instrument: SFC- 150 (Waters)
[0385] Column temperature: rt
[0386] Flow rate: 110 mL / min
[0387] Back pressure: 100 bar
[0388] Detection wavelength: 214 nm
[0389] Cycle time: 15 min
[0390] Sample solution: 200 mg dissolved in 15 mL CH3CN and isopropylalcohol Injection volume: 4.7 mL
[0391] Example 2A is the first eluting enantiomer with an ee of 100%. It has a negative specific optical rotation at [α]25589 nmin DCM.1H-NMR (400 MHz, CDCl₃) 67.55 (dd, J = 1.6, 8.4 Hz, 2H), 7.38 (d, J = 8.0 Hz, 2H), 7.15-7.08 (m, 2H), 7.03-6.97 (m, 1H), 5.05 (s, 2H), 4.39-4.33 (m, 1H), 4.14-4.05 (m, 2H), 2.84-2.75 (m, 1H), 2.61 (s, 3H), 2.50-2.40 (m, 1H). LCMS (ESI): m / z 450.1 (M+H)+.
[0392] Example 2B: (+)-2-(3-(2',5'-difluoro-[1,1'-biphenyl]-4-yl)-2-oxopyrrolidin-1-yl)-4-methylthiazole-5-sulfonamide
[0393] bitrarily assigned
[0394]
[0395] The title compound was prepared and further characterized by separation of the racemic mixture 2 as described for Example 2A. Example 2B is the second eluting enantiomer with an ee of 100%. It has a positive specific optical rotation at [α]25589 nmin DCM.1H-NMR (400 MHz, CDCl₃) 5 7.55 (dd, J = 1.4, 8.2 Hz, 2H), 7.38 (d, J = 8.4 Hz, 2H), 7.15-7.08 (m, 2H), 7.03-6.97 (m, 1H), 5.10 (s, 2H), 4.39-4.33 (m, 1H), 4.14-4.05 (m, 2H), 2.83-2.75 (m, 1H), 2.61 (s, 3H), 2.50-2.40 (m, 1H). LCMS (ESI): m / z 450.1 (M+H)+.Example 3: 2-(3-(2',5'-Difluoro-[1,1'-biphenyl]-4-yl)-2-oxoazepan-1-yl)-4-methylthiazole-5-sulfonamide
[0396]
[0397] Step 1: Methyl 6-((tert-butoxycarbonyl)amino)-2-(2',5'-difluoro- biphenyl1-4-yl)hexanoate
[0398]
[0399] (P3a)
[0400]
[0401] To a solution of compound P1b (4.0 g) in anhydrous DMSO (60 mL) was added NaH (0.67 g, 60%) at 0°C and the mixture was stirred at 0°C for 0.5 h, then tert-butyl (4-bromobutyl)carbamate (3.5 g) was added and the mixture was stirred at 50°C for 1 h, carefully quenched with ice-water (50 mL) and extracted with EA (3 x 60 mL). The combined organic layer was washed with brine (50 mL), dried over anhydrous Na₂SO₄, filtered, concentrated and purified by column chromatography (PE / EA = 72:18) to give compound P3a as a colorless oil. LCMS (ESI): m / z 334.3 (M-100)+.
[0402] Step 2: Methyl 6-amino-2-(2',5'-difluoro- biphenyl1-4-yl)hexanoate (P3b)
[0403]
[0404]
[0405] To a solution of compound P3a (2.4 g) in EA (20 mL) was added HCI (4.0M in EA, 10 mL) at 0°C. The mixture was stirred at 25°C for 1 h and concentrated in vacuo to give compound P3b as a white solid, which was used in the next step without further purification. LCMS (ESI): m / z 334.3 (M+H)+.
[0406] Step 3: 3-(2',5'-Difluoro- biphenyl1-4-yl)azepan-2-one (P3c)
[0407]
[0408] P3c
[0409]
[0410] A suspension of compound P3b (1.7 g) and terf-BuOK (1.2 g) in THF (15 mL) was stirred at 70°C for 2 h., cooled to rt, concentrated and purified by column chromatography (DCM / MeOH = 94:6) to give compound P3c as a white solid. LCMS (ESI): m / z 302.2 (M+H)+.
[0411] Step 4: 2-(3-(2',5'-Difluoro-[1,1'-bi
[0412]
[0413] |-4-yl)-2-i
[0414]
[0415] pan-1-yl)-N,N-bi
[0416]
[0417] -4-methylthiazole-5-sulfonamide (P3d)
[0418]
[0419] To a suspension of compound P1a (0.93 g) and compound P3c (0.62 g) in 1,4-dioxane (40 mL) was added XantPhos (0.12 g), Pd₂(dba)₃ (0.19 g) and Cs₂CO₃ (1.7 g) at 0°C under N2 and then the mixture was stirred at 100°C for 1 h under N2, cooled to rt, concentrated and purified by column chromatography (PE / EA = 7:3) to give compound P3d as a yellow solid. LCMS (ESI): m / z 718.3 (M+H)+.
[0420] Step 5: 2-(3-(2',5'-Difluoro-[1,1'-biphenyl]-4-yl)-2-oxoazepan-1-yl)-4-methylthiazole-5-sulfonamide (3)
[0421] To compound P3d (0.52 g) was added TFA (15 mL) at 0°C. The mixture was stirred at 60°C for 3 h under N2, concentrated and purified by reversed-phase flash chromatography (C18) (0.1% NH4HCO3 in water, 10 to 80% MeCN) to give compound 3 as a white solid. LCMS (ESI): m / z 478.2 (M+H)+.
[0422] Separation of Enantiomers of Example 3:
[0423] Example 3A: (–)-2-(3-(2',5'-Difluoro-[1,1'-biphenyl]-4-yl)-2-oxoazepan-1-yl)-4-methylthiazole-5-sulfonamide
[0424]
[0425] The title compound was prepared and further characterized by separation of the racemic mixture 3 by chiral SFC chromatography, using as stationary phase OJ 25×250 mm, 10 μm (Daicel) and as mobile phase 60 / 40 vol.% CO₂ / MeOH.The following conditions were applied:
[0426] Instrument: SFC-150 (Waters)
[0427] Column temperature: rt
[0428] Flow rate: 100 mL / min
[0429] Back pressure: 100 bar
[0430] Detection wavelength: 214 nm
[0431] Cycle time: 6 min
[0432] Sample solution: 200 mg dissolved in 80 mL MeOH and CH2CI2
[0433] Injection volume: 4.7 mL
[0434] Example 3A is the first eluting enantiomer with an ee of 100%. It has a negative specific optical rotation at [α]25589 nmin DCM.1H-NMR (400 MHz, CDCl₃) 67.55 (d, J = 7.2 Hz, 2H), 7.33 (d, J = 8.0 Hz, 2H), 7.18-7.07 (m, 2H), 7.02-6.96 (m, 1H), 5.33 (dd, J = 4.8, 14.8 Hz, 1H), 4.99 (s, 2H), 4.20 (d, J = 10.0 Hz, 1H), 3.91 (dd, J = 11.0, 15.0 Hz, 1H), 2.58 (s, 3H), 2.24-2.10 (m, 4H), 1.94-1.84 (m, 1H), 1.70-1.63 (m, 1H). LCMS (ESI): m / z 478.2 (M+H)+.
[0435] Example 3B: (+)-2-(3-(2',5'-Difluoro-[1,1'-biphenyl]-4-yl)-2-oxoazepan-1-yl)-4-methylthiazole-5-sulfonamide
[0436]
[0437] The title compound was prepared and further characterized by separation of the racemic mixture 3 as described for Example 3A. Example 3B is the second eluting enantiomer with an ee of 100%. It has a positive specific optical rotation at [α]25589 nmin DCM.1H-NMR (400 MHz, CDCl₃) 5 7.55 (dd, J = 1.4, 8.2 Hz, 2H), 7.33 (d, J = 8.4 Hz, 2H), 7.18-7.07 (m, 2H), 7.02-6.96 (m, 1H), 5.33 (dd, J = 4.8, 15.2 Hz, 1H), 4.99 (s, 2H), 4.20 (dd, J = 2.0, 10.0 Hz, 1H), 3.94-3.87 (m, 1H), 2.58 (s, 3H), 2.24-2.10 (m, 4H), 1.94-1.83 (m, 1H), 1.70-1.63 (m, 1H). LCMS (ESI): m / z 478.2 (M+H)+.
[0438] Example 4: 2-(3-(2',5'-Difluoro-[1,1'-biphenyl]-4-yl)-2-oxopyridin-1(2H)-yl)-4-methylthiazole-5-sulfonamide
[0439]
[0440] Step 1: 4'-Bromo-2,5-difluoro-1, T-biphenyl (P4a)
[0441] P4a
[0442]
[0443] To a solution of 2-(2,5-difluorophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (5.0 g) and 1-bromo-4-iodobenzene (8.9 g) in 1,4-dioxane (80 mL) and H₂O (16 mL) were added Pd(dppf)Cl₂ (1.2 g) and K₂CO₃ (13 g). The mixture was stirred at 100°C for 2 h under a N2 atmosphere, cooled to rt, diluted with water (400 mL) and extracted with DCM (3 x 400 mL). The combined organic layer was dried over anhydrous Na₂SO₄, filtered, concentrated and purified by column chromatography on silica gel (PE / EA = 30:1) to afford compound P4a as an off-white solid.
[0444] Step 2: (2-Oxo-1,2-dihydropyridin-3-yl)boronic acid (P4b)
[0445]
[0446] To a solution of 3-bromopyridin-2(1H)-one (4.0 g) and bis(pinacolato)diboron (12 g) in 1,4-dioxane (100 mL) were added Pd(dppf)Cl₂ (0.85 g) and KOAc (6.8 g). The mixture was stirred at 100°C for 16 h under a N2 atmosphere, cooled to rt and concentrated in vacuo to give compound P4b, which was used directly in the next reaction without purification. LCMS (ESI): m / z 152.2 (M+H)+.
[0447]
[0448] To a solution of compound P4a (4.4 g) and P4b (2.3 g) in 1,4-dioxane (60 mL) and H₂O (12 mL) were added Pd(dppf)Cl₂ (0.60 g) and K₂CO₃ (6.8 g). The mixture was stirred at 100°C for 16 h under a N2 atmosphere, cooled to rt, concentrated and purified by column chromatography on silica gel (DCM / MeOH = 5:1) to afford compound P4c as a brown solid. LCMS (ESI): m / z 284.1 (M+H)+.Step 4: 2-(3-(2',5'-Difluoro-n, T-biphenyl1-4-yl)-2-oxopyridin-1(2 / - / )-yl)- / \ / , / \ / -bis(4-methoxybenzyl)- 4-methylthiazole-5-sulfonamide (P4d)
[0449]
[0450] To a suspension of compound P1a (3.5 g) and compound P4c (2.1 g) in 1,4-dioxane (60 mL) was added XantPhos (0.43 g), Pd2(dba)3 (0.34 g) and Cs2CO3 (6.0 g) under N2 and then the mixture was stirred at 100°C for 1 h under N2, cooled to rt, concentrated and purified by column chromatography (PE / EA = 2:1) to give compound P4d as a brown solid. LCMS (ESI): m / z 700.2 (M+H)+.
[0451] Step 5: 2-(3-(2',5'-Difluoro- biphenyl1-4-yl)-2-oxopyridin-1(2 / 7)-yl)-4-methylthiazole-5-
[0452]
[0453] sulfonamide (4)
[0454] To compound P4d (0.72 g) was added TFA (10 mL). The mixture was stirred at 60°C for 1 h, cooled to rt, concentrated and purified by reversed-phase flash chromatography (C18) (0.1% NH4HCO3 in water, 10 to 100% MeCN) to give compound 4 as a white solid. LCMS (ESI): m / z 460.2 (M+H)+.
[0455] Example 5: 3-(2',5'-Difluoro-[1,1,-biphenyl]-4-yl)-1-(4-methyl-5-(S-methylsulfon-imidoyl)thiazol-2-yl)piperidin-2-one
[0456]
[0457] To a solution of tert-butyl nitrite (10.2 g) in MeCN (150 mL) was added CuCI (7.8 g) at 25°C and the mixture was stirred at 25°C for 10 min, then 4-methyl-5-(methylthio)-2-thiazolamine (10.5 g) was added and the mixture was stirred at 66°C for 1 h. On completion, the mixture was added dropwise into ice-water (200 mL) and extracted with EA (3 x 150 mL). The combined organic phase was washed with brine (200 mL), dried over anhydrous Na₂SO₄, filtered, concentrated and purified purified by column chromatography (PE / EA = 92:8) to give compound P5a as a yellow oil.1H-NMR (400 MHz, DMSO-d6) 52.42 (s, 3H), 2.36 (s, 3H).Step 2: (2-Chloro-4-methylthiazol-5-yl)(imino)(methyl)-A6-sulfanone (P5b)
[0458] P5b
[0459]
[0460] To a solution of P5a (3.3 g) in MeOH (30 mL) were added (NH4)2CO3 (3.5 g) and Phl(OAc)2 (14.8 g). The mixture was stirred at rt for 2 h, concentrated and purified by reversed-phase flash chromatography (C18) (10 mM NH4HCO3 in water, 10 to 50% MeCN) to give P5b as a white solid. LCMS (ESI): m / z 211.2 (M+H)+.
[0461] Step 3: tert-Butyl ((2-chloro-4-methylthiazol-5-yl)(methyl)(oxo)-A6-sulfaneylidene)carbamate (P5c)
[0462]
[0463] To a solution of P5b (2.9 g) in THF (20 mL) were added 4-dimethylaminopyridine (0.18 g), and di-terf-butyl dicarbonate (6.02 g). The mixture was stirred at 60°C for 2 h, diluted with icewater (60 mL) and extracted with EA (3 x 60 mL). The combined organic layer was washed with brine (80 mL), dried over anhydrous Na2SC>4, filtered, concentrated and purified by column chromatography (PE / EA = 4:1) to give P5c as a yellow soild. LCMS (ESI): m / z 255.1(M-55)+. Step 4: tert-Butyl ((2-(3-(2',5'-difluoro-n, T-biphenyl1-4-yl)-2-oxopiperidin-1-yl)-4-methylthiazol-5-yl)(methyl)(oxo)-A6-sulfaneylidene)carbamate (P5d)
[0464]
[0465] A suspension of P1e (500 mg), P5c (540 mg), XantPhos (100 mg), Pd2(dba)3 (159 mg) and Cs2CO3 (1.42 g) in 1,4-dioxane (20 mL) was stirred at 100°C for 1 h under N2, cooled to rt, concentrated and purified by column chromatography (PE / EA = 1:1) to give compound P5d as a yellow solid. LCMS (ESI): m / z 562.2 (M+H)+.
[0466] Step 5: 3-(2',5'-Difluoro-n, T-biphenyl1-4-yl)-1-(4-methyl-5-(S-methylsulfonimidoyl)thiazol-2-yl)piperidin-2-one (5)
[0467] To a suspension of P5d (545 mg) in DCM (4 mL) was added TFA (1 mL) at 0°C and the mixture was stirred at rt for 2 h, concentrated and purified by reversed-phase flash chromatography (C18) (10 mM NH4HCO3 in water, 10 to 50% MeCN) to give compound 5 as a white solid. LCMS (ESI): m / z 462.1 (M+H)+.Separation of Enantiomers / Diastereomers of Example 5:
[0468] Example 5A: (+)-3-(2',5'-Difluoro-[1, T-biphenyl]-4-yl)-1-(4-methyl-5-(S-methylsulfon-imidoyl)thiazol-2-yl)piperidin-2-one
[0469]
[0470] The title compound was prepared and further characterized by separation of the isomeric mixture 5 by chiral SFC chromatography, using as stationary phase AD 25x250 mm, 10 pm (Daicel) and as mobile phase 55 / 45 vol.% CC>2 / [IPA / ACN = 1:1],
[0471] Example 5A is the first eluting isomer with an ee of 100%. It has a positive specific optical rotation at [a]25589 nmin MeCN.1H-NMR (400 MHz, DMSO-d6) 6 7.54 (d, J = 8.0 Hz, 2H), 7.45-7.35 (m, 4H), 7.29-7.23 (m, 1H), 4.69 (s, 1H), 4.33-4.29 (m, 1H), 4.15-4.08 (m, 2H), 3.14 (s, 3H), 2.55 (s, 3H), 2.23-2.17 (m, 1H), 2.12-2.02 (m, 4H). LCMS (ESI): m / z 462.1 (M+H)+.
[0472] The following conditions were applied:
[0473] Instrument: SFC- 150 (Waters)
[0474] Column temperature: rt
[0475] Flow rate: 100 mL / min
[0476] Back pressure: 100 bar
[0477] Detection wavelength: 214 nm
[0478] Cycle time: 6.7 min
[0479] Sample solution: 400 mg dissolved in 100 mL I PA and CH2CI2
[0480] Injection volume: 2 mL
[0481] Example 5B: (+)-3-(2',5'-Difluoro-[1, T-biphenyl]-4-yl)-1-(4-methyl-5-(S-methylsulfon-imidoyl)thiazol-2-yl)piperidin-2-one
[0482]
[0483] bitrarily assigned Example 5B is the second eluting isomer with an ee of 100%. It has a positive specific optical rotation at [a]25589 nmin MeCN.1H-NMR (400 MHz, DMSO-d6) 6 7.54 (d, J = 8.0 Hz, 2H), 7.45-7.35 (m, 4H), 7.29-7.23 (m, 1H), 4.68 (s, 1H), 4.34-4.30 (m, 1H), 4.15-4.08 (m, 2H), 3.15 (s, 3H), 2.55 (s, 3H), 2.23-2.19 (m, 1H), 2.12-2.01 (m, 4H). LCMS (ESI): m / z 462.1 (M+H)+.Example 5C: (-)-3-(2',5'-Difluoro-[1,1'-biphenyl]-4-yl)-1-(4-methyl-5-(S-methylsulfon-imidoyl)thiazol-2-yl)piperidin-2-one
[0484]
[0485] rbitrarily assigned Example 5C is the third eluting isomer with an ee of 99.0%. It has a negative specific optical rotation at [a]25589 nmin MeCN.1H-NMR (400 MHz, DMSO-d6) 6 7.54 (d, J = 8.4 Hz, 2H), 7.45-7.35 (m, 4H), 7.29-7.23 (m, 1 H), 4.69 (s, 1 H), 4.33-4.29 (m, 1 H), 4.15-4.08 (m, 2H), 3.14 (s, 3H), 2.55 (s, 3H), 2.23-2.17 (m, 1H), 2.12-2.01 (m, 4H). LCMS (ESI): m / z 462.1 (M+H)+.
[0486] Example 5D: (-)-3-(2',5'-Difluoro-[1,1,-biphenyl]-4-yl)-1-(4-methyl-5-(S-methylsulfon-imidoyl)thiazol-2-yl)piperidin-2-one
[0487]
[0488] bitrarily assigned Example 5D is the fourth eluting isomer with an ee of 99.9%. It has a negative specific optical rotation at [a]25589 nmin MeCN.1H-NMR (400 MHz, DMSO-d6) 6 7.54 (d, J = 8.4 Hz, 2H), 7.45-7.35 (m, 4H), 7.29-7.23 (m, 1H), 4.68 (s, 1H), 4.34-4.30 (m, 1H), 4.15-4.08 (m, 2H), 3.15 (s, 3H), 2.55 (s, 3H), 2.23-2.19 (m, 1H), 2.12-2.01 (m, 4H). LCMS (ESI): m / z 462.1 (M+H)+.
[0489] Example 6: 3-(2',5'-Difluoro-[1,1,-biphenyl]-4-yl)-1-(4-methyl-5-(S-methylsulfon-imidoyl)thiazol-2-yl)pyrrolidin-2-one
[0490]
[0491] Step 1: tert-Butyl ((2-(3-(2',5'-difluoro-n,1'-biphenyl1-4-yl)-2-oxopyrrolidin-1-yl)-4-methylthiazol-5-yl)(methyl)(oxo)-A6-sulfaneylidene)carbamate (P6a)
[0492]
[0493] A suspension of P2b (1.0 g), P5c (1.14 g), XantPhos (211 mg), Pd2(dba)3 (338 mg) and Cs2CO3 (2.98 g) in 1,4-dioxane (40 mL) was stirred at 100°C for 1 h under N2, cooled to rt, concentrated and purified by column chromatography (PE / EA = 1:3) to give compound P6a as a yellow solid. LCMS (ESI): m / z 548.0 (M+H)+.
[0494] Step 2: 3-(2',5'-Difluoro-n,1'-biphenyl1-4-yl)-1-(4-methyl-5-(S-methylsulfonimidoyl)thiazol-2-yl)pyrrolidin-2-one (6)
[0495] To a suspension of P6a (800 mg) in DCM (8 mL) was added TFA (2 mL) at 0°C and the mixture was stirred at rt for 2 h, concentrated and purified by reversed-phase flash chromatography (C18) (10 mM NH4HCO3 in water, 30 to 80% MeCN) to give compound 6 as a white solid. LCMS (ESI): m / z 448.2 (M+H)+.
[0496] Separation of Enantiomers / Diastereomers of Example 6:
[0497] Example 6A: (+)-3-(2',5,-Difluoro-[1, T-biphenyl]-4-yl)-1-(4-methyl-5-(S-methyl-sulfon-,imidoyl)thiazol-2-yl)pyrrolidin-2-one
[0498]
[0499] The title compound was prepared and further characterized by separation of the isomeric mixture 6 by chiral SFC chromatography, using as stationary phase OJ 25x250 mm, 10 pm (Regis) and as mobile phase 65 / 35 vol.% CO2 / IPA.
[0500] Example 6A is the first eluting isomer with an ee of 98.6%. It has a positive specific optical rotation at [a]25589 nmin MeCN.1H-NMR (400 MHz, DMSO-d6) 6 7.58 (dd, J = 1.2, 8.0 Hz, 2H), 7.47-7.35 (m, 4H), 7.30-7.24 (m, 1H), 4.77 (s, 1H), 4.25 (t, J = 9.4 Hz, 2H), 4.05-3.98 (m, 1H), 3.17 (s, 3H), 2.74-2.66 (m, 1H), 2.55 (s, 3H), 2.40-2.30 (m, 1H). LCMS (ESI): m / z 448.2 (M+H)+.
[0501] The following conditions were applied:
[0502] Instrument: SFC- 150 (Waters)
[0503] Column temperature: rt
[0504] Flow rate: 120 mL / min
[0505] Back pressure: 100 bar
[0506] Detection wavelength: 214 nm
[0507] Cycle time: 14.85 min
[0508] Sample solution: 400 mg dissolved in 40 mL MeCN and CH2CI2
[0509] Injection volume: 4 mLExample 6B: (+)-3-(2',5'-Difluoro-[1, T-biphenyl]-4-yl)-1-(4-methyl-5-(S-methyl-sulfon-,imidoyl)thiazol-2-yl)pyrrolidin-2-one
[0510]
[0511] Example 6B is the second eluting isomer with an ee of 98.4%. It has a positive specific optical rotation at [a]25589 nmin MeCN.1H-NMR (400 MHz, DMSO-d6) δ 7.58 (dd, J = 1.2, 8.0 Hz, 2H), 7.47-7.35 (m, 4H), 7.30-7.24 (m, 1H), 4.77 (s, 1H), 4.29-4.23 (m, 2H), 4.04-3.97 (m, 1H), 3.17 (s, 3H), 2.74-2.66 (m, 1H), 2.55 (s, 3H), 2.40-2.31 (m, 1H). LCMS (ESI): m / z 448.2 (M+H)+.
[0512] Example 6C: (-)-3-(2',5'-Difluoro-[1,1,-biphenyl]-4-yl)-1-(4-methyl-5-(S-methyl-sulfon-,imidoyl)thiazol-2-yl)pyrrolidin-2-one
[0513]
[0514] Example 6C is the third eluting isomer with an ee of 97.5%. It has a negative specific optical rotation at [a]25589 nmin MeCN.1H-NMR (400 MHz, DMSO-d6) 67.58 (dd, J = 1.2, 8.0 Hz, 2H), 7.46-7.35 (m, 4H), 7.30-7.24 (m, 1H), 4.77 (s, 1H), 4.29-4.23 (m, 2H), 4.04-3.97 (m, 1H), 3.17 (s, 3H), 2.73-2.66 (m, 1H), 2.55 (s, 3H), 2.40-2.30 (m, 1H). LCMS (ESI): m / z 448.2 (M+H)+.
[0515] Example 6D: (-)-3-(2',5'-Difluoro-[1,1,-biphenyl]-4-yl)-1-(4-methyl-5-(S-methyl-sulfon-,imidoyl)thiazol-2-yl)pyrrolidin-2-one
[0516]
[0517] Example 6D is the fourth eluting isomer with an ee of 98.5%. It has a negative specific optical rotation at [a]25589 nmin MeCN.1H-NMR (400 MHz, DMSO-d6) 67.58 (dd, J = 1.2, 8.0 Hz, 2H), 7.47-7.35 (m, 4H), 7.30-7.24 (m, 1H), 4.78 (s, 1H), 4.25 (t, J = 9.6 Hz, 2H), 4.05-3.98 (m, 1H), 3.17 (s, 3H), 2.74-2.66 (m, 1H), 2.55 (s, 3H), 2.40-2.30 (m, 1H). LCMS (ESI): m / z 448.2 (M+H)+.Example 7: 3-(2',5'-Difluoro-[1 '-biphenylJ-^yQ-l-^-methyl-S-fS-methylsulfon-imidoyQthiazol^-yQpyridin^lHJ-one
[0518]
[0519] Step 1: tert-Butyl ((2-(3-(2',5'-difluoro-n, T-biphenyl1-4-yl)-2-oxopyridin-1(2 / 7)-yl)-4-methylthiazol-5-yl)(methyl)(oxo)-A6-sulfaneylidene)carbamate (P7a)
[0520]
[0521] A suspension of P4c (850 mg), P5c (931 mg), XantPhos (173 mg), Pd2(dba)3 (274 mg) and Cs2CO3 (2.44 g) in 1,4-dioxane (15 mL) was stirred at 100°C for 1 h under N2, cooled to rt, concentrated and purified by column chromatography on silica gel (PE / EA = 1:1) to give compound P7a as a brown solid. LCMS (ESI): m / z 558.0 (M+H)+.
[0522] Step 2: 3-(2',5'-Difluoro-n, T-biphenyl1-4-yl)-1-(4-methyl-5-(S-methylsulfonimidoyl)thiazol-2-yl)pyridin-2(1 / - / )-one (7)
[0523] To a suspension of P7a (450 mg) in DCM (4 mL) was added TFA (1 mL) at 0°C and the mixture was stirred at rt for 2 h, concentrated and purified by reversed-phase flash chromatography (C18) (10 mM NH4HCO3 in water, 30 to 80% MeCN) to give compound 7 as a white solid. LCMS (ESI): m / z 458.1 (M+H)+.
[0524] Separation of Enantiomers of Example 7:
[0525] Example 7A: (+)-3-(2',5,-Difluoro-[1, T-biphenyl]-4-yl)-1-(4-methyl-5-(S-methylsulfon-imidoyl)thiazol-2-yl)pyridin-2(1H)-one
[0526]
[0527] The title compound was prepared and further characterized by separation of the enantiomeric mixture 7 by chiral SFC chromatography, using as stationary phase (R, R) WHELK-01 25x250 mm, 10 pm (Regis) and as mobile phase 65 / 35 vol.% CO2 / [IPA / ACN = 1:1], Example 7A is the first eluting enantiomer with an ee of 100%. It has a positive specific optical rotation at [a]25589 nmin MeCN.1H-NMR (400 MHz, DMSO-d6) 68.82 (dd, J = 2.0, 7.2 Hz,1 H), 7.95 (dd, J = 1.8, 7.0 Hz, 1H), 7.85 (d, J = 8.4 Hz, 2H), 7.68 (d, J = 7.2 Hz, 2H), 7.52-7.47 (m, 1H), 7.44-7.38 (m, 1H), 7.33-7.26 (m, 1H), 6.81 (t, J = 7.2 Hz, 1H), 4.93 (1 H), 3.24 (s, 3H), 2.65 (s, 3H). LCMS (ESI): m / z 458.1 (M+H)+.
[0528] The following conditions were applied:
[0529] Instrument: SFC-150 (Waters)
[0530] Column temperature: rt
[0531] Flow rate: 120 mL / min
[0532] Back pressure: 100 bar
[0533] Detection wavelength: 214 nm
[0534] Cycle time: 10.5 min
[0535] Sample solution: 150 mg dissolved in 80 mL MeCN / IPA and CH2CI2
[0536] Injection volume: 4.5 mL
[0537] Example 7B: (-)-3-(2',5'-Difluoro-[1,1,-biphenyl]-4-yl)-1-(4-methyl-5-(S-methylsulfon-imidoyl)thiazol-2-yl)pyridin-2(1H)-one
[0538]
[0539] Example 7B is the second eluting enantiomer with an ee of 99.3%. It has a negative specific optical rotation at [a]25589 nmin MeCN.1H-NMR (400 MHz, DMSO-de) 68.82 (dd, J = 2.0, 7.2 Hz, 1H), 7.95 (dd, J = 1.8, 7.0 Hz, 1H), 7.85 (d, J = 8.4 Hz, 2H), 7.69-7.67 (m, 2H), 7.52-7.47 (m, 1H), 7.44-7.38 (m, 1H), 7.32-7.26 (m, 1H), 6.80 (t, J = 7.0 Hz, 1H), 4.93 (1 H), 3.24 (s, 3H), 2.65 (s, 3H). LCMS (ESI): m / z 458.1 (M+H)+.
[0540] Example 8: 2-(3-(5-(2,5-Difluorophenyl)thiophen-2-yl)-2-oxopiperidin-1-yl)-4-methylthiazole-5-sulfonamide
[0541]
[0542] Step 1: Methyl 2-(5-(2,5-difluorophenyl)thiophen-2-yl)acetate (P8a)
[0543]
[0544] A mixture of methyl 2-(5-bromothiophen-2-yl)acetate (1.0 g), (2,5-difluorophenyl)boronic acid (0.77 g), Na2COs (1.06 g) and Pd(dppf)Ch (293 mg) in 1,4-dioxane / H2O (5:1, v / v, 6 mL) was degassed with N2, heated to 100°C and stirred for 2 h, cooled to rt, diluted with water and extracted with Et20 (3 x). The combined organic layer was washed with brine, dried over Na2SC>4,filtered, concentrated and purified by by flash column chromatography (DCM / MeOH = 95:5) to give compound P8a as a pale yellow oil. LCMS (ESI): m / z 269.2 (M+H)+.
[0545] Step 2: 2-(3-(5-(2,5-Difluorophenyl)thiophen-2-yl)-2-oxopiperidin-1-yl)-4-methylthiazole-5-sulfonamide (8)
[0546] Compound P8a was treated similar as described in Example 1, Step 3 to Step 7, to give compound 8 as a white solid.1H-NMR (400 MHz, CDCI3) 57.35 (d, J = 3.2 Hz, 1 H), 7.31-7.27 (m, 1H), 7.12-7.06 (m, 1H), 6.99 (d, J = 4.0 Hz, 1H), 6.95-6.89 (m, 1H), 4.98 (s, 2H), 4.38-4.32 (m, 1 H), 4.24-4.10 (m, 2H), 2.61 (s, 3H), 2.49-2.44 (m, 1H), 2.32-2.24 (m, 2H), 2.13-2.05 (m, 1H).
[0547] 19F-NMR (376 MHz, CDCI3) 6 -118.67 (d, J = 18.4 Hz), -119.83 (d, J = 17.7 Hz). LCMS (ESI): m / z 470.0 (M+H)+.
[0548] Example 9: 2-(3-(2',5'-Difluoro-[1, T-biphenyl]-4-yl)-3-methyl-2-oxopiperidin-1-yl)-4-methylthiazole-5-sulfonamide
[0549]
[0550] Step 1: 2-(3-(2',5'-Difluoro-n,1'-biphenyl1-4-yl)-3-methyl-2-oxopiperidin-1-yl)- / \ / , / \ / -bis(4-methoxybenzyl)-4-methylthiazole-5-sulfonamide (P8a)
[0551]
[0552] A solution of compound P1a (0.25 g) in anhydrous THF (8 mL) was treated with LiHMDS (1 M in THF; 0.53 mL) at 0°C under N2. After stirring for 30 min, Mel (44 pL) was added. The mixture was stirred at 0°C for 2 h, quenched with sat. aq. NH4CI and extracted with EtOAc (3 x). The combined organic layer was washed with brine, dried over Na2SO4, filtered, concentrated and purified by flash column chromatography (PE / EA = 65:35) to afford compound P9a as a yellow oil. LCMS (ESI): m / z 718.2(M+H)+.
[0553] Step 2: 2-(3-(2',5'-Difluoro- biphenyl1-4-yl)-3-methyl-2-oxopiperidin-1-yl)-4-methylthiazole-5-sulfonamide (9)
[0554]
[0555] Compound P9a was treated similar as described in Example 1, Step 7, to give compound 9 as a white solid.1H-NMR (400 MHz, DMSO-d6) 5 7.67 (s, 2H), 7.56 (d, J = 6.8 Hz, 2H), 7.44-7.34 (m, 4H), 7.29-7.23 (m, 1H), 4.20-4.05 (m, 2H), 2.50 (s, 3H), 2.34-2.29 (m, 1H), 2.14-2.06 (m, 1H), 1.98-1.95 (m, 1H), 1.74-1.64 (m, 1H), 1.64 (s, 3H).19F-NMR (376 MHz, DMSO-d6) 5 -118.30 (d, J = 18.4 Hz), -123.85 (d, J = 18.1 Hz). LCMS (ESI): m / z 478.1 (M+H)+.Example 10: 2-(3-(3,3'-Difluoro-[1, T-biphenyl]-4-yl)-2-oxopiperidin-1-yl)-4-methylthiazole-5-sulfonamide
[0556]
[0557] Step 1: 3-(4-Bromo-2-fluorophenyl)piperidin-2-one (P10a)
[0558] A
[0559] p-ioa
[0560] F A
[0561] Methyl 2-(4-bromo-2-fluorophenyl)acetate was treated similar as described in Example 1, Step 3 to Step 5, to give compound P10a as a white solid. LCMS (ESI): m / z 272.2 (M+H)+.
[0562] Step 2: 3-(3,3'-Difluoro-H,1'-biphenyl1-4-yl)piperidin-2-one (P10b)
[0563] p-iob
[0564]
[0565] To a suspension of (3-fluorophenyl)boronic acid (185 mg) and compound P10a (300 mg), was treated similar as described in Example 8, Step 1 to afford P10b as a yellow oil. LCMS (ESI): m / z 288.1 (M+H)+.
[0566] Step 3: 2-(3-(3,3'-Difluoro- biphenyl1-4-yl)-2-oxopiperidin-1-yl)-4-methylthiazole-5-sulfonamide (10)
[0567]
[0568] Compound P10b was treated similar as described in Example 1, Step 6 to Step 7, to give compound 10 as a white solid. H-NMR (400 MHz, DMSO-d6) 6 7.66 (s, 2H), 7.61-7.45 (m, 6H), 7.26-7.21 (m, 1H), 4.42-4.38 (m, 1H), 4.28-4.23 (m, 1H), 4.03-3.95 (m, 1H), 2.51 (s, 3H), 2.20-2.00 (m, 4H).19F-NMR (376 MHz, DMSO-d6) 6 -112.69 (s), -116.62 (s). LCMS (ESI): m / z 464.0 (M+H)+.
[0569] Example 11: 2-(3-(2',5'-Difluoro-[1, T-biphenyl]-4-yl)-3-fluoro-2-oxopiperidin-1-yl)-4-methylthiazole-5-sulfonamide
[0570]
[0571] Step 1: 2-(3-(2',5'-Difluoro-n, T-biphenyl1-4-yl)-3-fluoro-2-oxopiperidin-1-yl)- / \ / , / \ / -bis(4-methoxybenzyl)-4-methylthiazole-5-sulfonamide (P11 a)
[0572]
[0573] A solution of compound P1a (0.5 g) in anhydrous THF (16 mL) was treated with LiHMDS (1 M in THF; 1.1 mL) at 0°C under N2. After stirring for 30 min, / V-fluorobenzenesulfonimide (658 mg) was added. The mixture was stirred at 0°C for 2 h and then warmed to rt and stirred for 4 h, quenched with sat. aq. NH4CI and extracted with EtOAc (3 x). The combined organic layer was washed with brine, dried over Na2SC>4, filtered, concentrated and purified by flash column chromatography (PE / EA = 3:1) to afford compound P11a as a yellow oil. LCMS (ESI): m / z 722.2(M+H)+.
[0574] Step 2: 2-(3-(2',5'-Difluoro-n,1'-biphenyl1-4-yl)-3-fluoro-2-oxopiperidin-1-yl)-4-methylthiazole-5-sulfonamide (11)
[0575] Compound P11 a was treated similar as described in Example 1, Step 7, to give compound 11 as a white solid after purification by reversed-phase flash chromatography (C18) (0.1% NH4HCO3 in water, 40 to 90% MeCN).1H-NMR (400 MHz, DMSO-d6) 57.75 (s, 2H), 7.64 (d, J = 8.0 Hz, 2H), 7.55 (d, J = 8.4 Hz, 2H), 7.49-7.37 (m, 2H), 7.32-7.26 (m, 1H), 4.38-4.31 (m, 1H), 4.24-4.17 (m, 1H), 2.67-2.57 (m, 1H), 2.52 (s, 3H), 2.50-2.44 (m, 1H), 2.20-2.13 (m, 1H), 1.99-1.94 (m, 1H).19F-NMR (376 MHz, DMSO-d6) 5 -118.24 (d, J = 19.6 Hz), -123.84 (d, J = 19.2 Hz), -143.46 (s). LCMS (ESI): m / z 482.1 (M+H)+.
[0576] In addition, the also compound 11-1 was isolated:
[0577] 2-(5-(2',5,-Difluoro-[1,1'-biphenyl]-4-yl)-6-oxo-3,6-dihydropyridin-1(2H)-yl)-4-methylthiazole-5-sulfonamide (11-1)
[0578]
[0579] 1H-NMR (400 MHz, DMSO-d6) 57.68 (s, 2H), 7.62-7.58 (m, 4H), 7.56-7.37 (m, 2H), 7.31-7.25 (m, 2H), 4.43 (t, J = 6.8 Hz, 2H), 2.79-2.74 (m, 2H), 2.50 (s, 3H).19F-NMR (376 MHz, DMSO-d6) 5 -118.30 (d, J = 19.6 Hz), -123.76 (d, J = 18.4 Hz). LCMS (ESI): m / z 462.1 (M+H)+.Example 12: 4-Methyl-2-(2-oxo-3-(2',3,5'-trifluoro-[1,1,-biphenyl]-4-yl)piperidin-1-yl)thiazole-5-sulfonamide
[0580]
[0581] Using (2,5-difluorophenyl)boronic acid instead of (3-fluorophenyl)boronic acid as described in Example 10, compound 12 was obtained as a white solid.1H-NMR (400 MHz, DMSO-d6) 67.65 (s, 2H), 7.53-7.38 (m, 5H), 7.33-7.27 (m, 1H), 4.42-4.38 (m, 1H), 4.30-4.25 (m, 1 H), 4.01-3.95 (m, 1 H), 2.51 (s, 3H), 2.21-2.01 (m, 4H).19F-NMR (376 MHz, DMSO-d6) 6 -116.71 (s), -118.15 (d, J = 17.7 Hz), -123.59 (d, J = 18.1 Hz). LCMS (ESI): m / z 482.1 (M+H)+.
[0582] Example 13: 3-(2',5'-Difluoro-[1, T-biphenyl]-4-yl)-1-(4-methyl-5-(methylsulfinyl)thiazol-2-yl)piperidin-2-one
[0583]
[0584] Step 1: 3-(2',5'-Difluoro-n,1'-biphenyl1-4-yl)-1-(4-methyl-5-(methylthio)thiazol-2-yl)piperidin-2-one (P13a)
[0585]
[0586] A suspension of compound P1e (150 mg), 2-chloro-4-methyl-5-(methylthio)thiazole (112 mg), XantPhos (30 mg), Pd2(dba)3 (24 mg) and Cs2CO3 (340 mg) in 1,4-dioxane (5 mL) was degassed with N2 and then the mixture was stirred at 100°C for 1h under N2, cooled to rt, concentrated and purified by column chromatography (PE / EA = 7:3) to give compound P13a as a yellow solid. LCMS (ESI): m / z 431.1 (M+H)+.
[0587] 2: 3-(2',5'-Difluoro-F1, T-biphenyll-4-yl)-1-(4-methyl-5-
[0588]
[0589] l-2-yl)piperidin-2-one (13)
[0590] To a solution of compound P13a (90 mg) in DCM (2 mL) at 0°C was added metachloroperoxybenzoic acid (43 mg). After stirring for 1 h, the mixture was quenched with sat. aq. Na2SC>3, concentrated and purified by reversed-phase flash chromatography (C18) (0.1% NH4HCO3 in water, 10 to 80% MeCN) to afford compound 13 as a white solid.1H-NMR (400 MHz, DMSO-d6) 6 7.55 (d, J = 7.6 Hz, 2H), 7.46-7.35 (m, 4H), 7.29-7.24 (m, 1H), 4.35-4.31 (m, 1H), 4.15-4.10 (m, 2H), 2.91 (d, J = 2.4 Hz, 3H), 2.43 (d, J = 1.2 Hz, 3H), 2.20-2.05 (m, 4H).19F-NMR (376 MHz, DMSO-d6) 6 -118.37 (d, J = 18.1 Hz), -123.90 to -123.96 (m). LCMS (ESI): m / z 447.1 (M+H)+.Example 14: 3-(2',5'-Difluoro-[1, T-biphenyl]-4-yl)-1-(4-methyl-5-(methylsulfonyl)thiazol-2-yl)piperidin-2-one
[0591]
[0592] A solution of compound P13a (110 mg) in dry DCM (2 mL) at 0°C was treated with meta-chloroperoxybenzoic acid (0.11 g). After stirring for 2 h at rt, the mixture was purified by reversed-phase flash chromatography (C18) (0.1% NH4HCO3 in water, 10 to 80% MeCN) to afford compound 14 as a white solid.1H-NMR (400 MHz, DMSO-d6) 6 7.55 (d, J = 6.8 Hz, 2H), 7.46-7.35 (m, 4H), 7.29-7.24 (m, 1H), 4.36-4.32 (m, 1H), 4.17-4.10 (m, 2H), 3.29 (s, 3H), 2.56 (s, 3H), 2.23-2.02 (m, 4H).19F-NMR (376 MHz, DMSO-d6) 6 -118.36 (d, J = 18.4 Hz), -123.92 (d, J = 18.4 Hz). LCMS (ESI): m / z 463.1 (M+H)+.
[0593] Example 15: 2-(3-(2',5'-Difluoro-[1, T-biphenyl]-4-yl)-2-oxopiperidin-1-yl)-A / ,4-dimethylthiazole-5-sulfonamide
[0594]
[0595]
[0596] To a solution of 2-chloro-4-methylthiazole-5-sulfonyl chloride (500 mg) in anhydrous DCM (11 mL) at 0°C were added triethylamine (607 pL) and / V-methyl-4-methoxybenzylamine (394 mg). The mixture was stirred at rt for 2 h, quenched with sat. aq. NH4CI and extracted with DCM (3 x). The combined organic layer was washed with brine, dried over Na2SC>4, filtered, concentrated and purified by flash column chromatography (PE / EA = 8:2) to afford compound P15a as a yellow solid. LCMS (ESI): m / z 347.1 (M+H)+.
[0597] Step 2: 2-(3-(2',5'-Difluoro- biphenyl1-4-yl)-2-oxopiperidin-1-yl)- / \ / ,4-dimethylthiazole-5-sulfonamide (15)
[0598]
[0599] Compound P15a was treated similar as described in Example 1, Step 6 to Step 7, to give compound 15 as a white solid after purification by reversed-phase flash chromatography (C18) (0.1% NH4HCO3 in water, 10 to 80% MeCN).1H-NMR (400 MHz, DMSO-d6) 67.70 (q, J = 4.9 Hz, 1H), 7.54 (dd, J = 1.4, 8.2 Hz, 2H), 7.46-7.35 (m, 4H), 7.29-7.23 (m, 1H), 4.36-4.31 (m, 1H), 4.15-4.08 (m, 2H), 2.51-2.48 (m, 6H), 2.21-2.02 (m, 4H).19F-NMR (376 MHz, DMSO-d6) 6 -118.37 (d, J = 17.7 Hz), -123.93 (d, J = 17.7 Hz). LCMS (ESI): m / z 478.1 (M+H)+.Example 16: 2-(3-(5'-Ethynyl-2'-fluoro-[1,1,-biphenyl]-4-yl)-2-oxopiperidin-1-yl)-4-methylthiazole-5-sulfonamide
[0600]
[0601] Step 1: ((4-Fluoro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethynyl)trimethylsilane (P16a)
[0602]
[0603] A suspension of ((3-bromo-4-fluorophenyl)ethynyl)trimethylsilane (1.2 g), bis(pinacolato)diboron (1.24 g), Pd(dppf)Ch (0.16 g) and KOAc (0.87 g) in 1,4-dioxane (20 mL) was stirred at 80°C under N2 for 4 h. After filtration and concentration, the crude product was purified by flash column chromatography (PE / EA = 95:5) to afford compound P16a as a pale yellow oil. LCMS (ESI): m / z 319.2 (M+H)+.
[0604] Step 2: 2-(3-(4-Bromophenyl)-2-oxopiperidin-1-yl)-4-methylthiazole-5-sulfonamide (P16b)
[0605]
[0606] Methyl 2-(4-bromophenyl)acetate was treated similar as described in Example 1, Step 3 to Step 7, to give compound P16b as a yellow solid. LCMS (ESI): m / z 430.0 (M+H)+.
[0607] Step 3: 2-(3-(2'-Fluoro-5'-((trimethylsilyl)ethynyl)-H,1'-biphenyl1-4-yl)-2-oxopiperidin-1-yl)-4-methylthiazole-5-sulfonamide (P16c)
[0608]
[0609] A mixture of compound P16b (800 mg), compound P16a (713 mg), Na2COs (495 mg) and Pd(dppf)Ch (85 mg) in 1,4-dioxane / H2O (5:1, v / v, 3 mL) was degassed with N2, heated to 100°C and stirred for 2 h, cooled to rt, concentrated in vacuo and purified by column chromatography (PE / EA = 3:1) to afford compound P16c as a yellow solid. LCMS (ESI): m / z 542.2 (M+H)+.
[0610] Step 4: 2-(3-(5'-Ethynyl-2'-fluoro-n, T-biphenyl1-4-yl)-2-oxopiperidin-1-yl)-4-methylthiazole-5-sulfonamide (16)
[0611] To a solution of compound P16c (200 mg) in MeCN / THF (1:1, v / v, 4 mL) was added CsF (561 mg). The mixture was stirred at 50°C for 3 h, concentrated and purified by reversed-phase flash chromatography (C18) (0.1% NH4HCO3 in water, 40 to 90% MeCN) to afford compound P16 as a white solid.1H-NMR (400 MHz, DMSO-d6) 67.66-7.62 (m, 3H), 7.55-7.52 (m, 3H), 7.39-7.33(m, 3H), 4.33-4.28 (m, 1 H), 4.24 (s, 1 H), 4.15-4.07 (m, 2H), 2.50 (s, 3H), 2.23-2.17 (m, 1 H), 2.12-2.00 (m, 3H).19F-NMR (376 MHz, DMSO-d6) 6 -115.69 (s). LCMS (ESI): m / z 470.1 (M+H)+.
[0612] In addition, also compound 16-1 was isolated:
[0613] 2-(3-(5'-Acetyl-2'-fluoro-[1, T-biphenyl]-4-yl)-2-oxopiperidin-1-yl)-4-methylthiazole-5-sulfonamide (16-1)
[0614]
[0615] 1H-NMR (400 MHz, DMSO-d6) 68.10 (dd, J = 2.4, 7.6 Hz, 1H), 8.03-7.99 (m, 1H), 7.66 (s, 2H), 7.59-7.57 (m, 2H), 7.51-7.46 (m, 1H), 7.42 (d, J = 8.4 Hz, 2H), 4.34-4.30 (m, 1H), 4.16-4.08 (m, 2H), 2.64 (s, 3H), 2.51 (s, 3H), 2.23-2.01 (m, 4H).19F-NMR (376 MHz, DMSO-d6) 6 -111.47 (s). LCMS (ESI): m / z 488.1 (M+H)+.
[0616] Example 17: 2-(3-(2'-Ethynyl-5'-fluoro-[1,1,-biphenyl]-4-yl)-2-oxopiperidin-1-yl)-4-methylthiazole-5-sulfonamide
[0617]
[0618] Using ((2-bromo-4-fluorophenyl)ethynyl)trimethylsilane (synthesis described in Adv. Synth. Catal. 2024:366; 1523) instead of ((3-bromo-4-fluorophenyl)ethynyl)trimethylsilane as described in Example 16, compound 17 was obtained as a white solid.1H-NMR (400 MHz, DMSO-d6) 6 7.68-7.65 (m, 3H), 7.57 (d, J = 8.0 Hz, 2H), 7.36 (d, J = 8.4 Hz, 2H), 7.34-7.30 (m, 1H), 7.27-7.22 (m, 1H), 4.34-4.28 (m, 1H), 4.16-4.08 (m, 3H), 2.51 (s, 3H), 2.24-2.18 (m, 1H), 2.12-2.00 (m, 3H).19F-NMR (376 MHz, DMSO-d6) 6-110.11 (s). LCMS (ESI): m / z 470.1 (M+H)+.
[0619] In addition, also compound 17-1 was isolated:
[0620] 2-(3-(2'-Acetyl-5'-fluoro-[1, T-biphenyl]-4-yl)-2-oxopiperidin-1-yl)-4-methylthiazole-5-sulfonamide (17-1)
[0621]
[0622] 1H-NMR (400 MHz, DMSO-d6) 67.71 (dd, J = 5.6, 8.4 Hz, 1H), 7.57 (br s, 2H), 7.35-7.28 (m, 6H), 4.32-4.28 (m, 1H), 4.14-4.08 (m, 2H), 2.51 (s, 3H), 2.23-1.99 (m, 7H).19F-NMR (376 MHz, DMSO-d6) 6 -109.41 (s). LCMS (ESI): m / z 488.0 (M+H)+.Example 18: 2-(3-(2'-Fluoro-[1,1'-biphenyl]-4-yl)-2-oxopiperidin-1-yl)-4-methylthiazole-5-sulfonamide
[0623]
[0624] Step 1: 3-(2'-Fluoro- biphenyl1-4-yl)piperidin-2-one (P18a)
[0625]
[0626]
[0627] A mixture of 3-(4-bromophenyl)piperidin-2-one (300 mg), (2-fluorophenyl)boronic acid (200 mg), Na2COs (315 mg) and Pd(dppf)Ch (87 mg) in 1,4-dioxane / H2O (5:1, v / v, 3 mL) was degassed with N2, heated to 100°C and stirred for 2 h, cooled to rt, concentrated in vacuo and purified by column chromatography (DCM / MeOH = 96:4) to afford compound P18a as a yellow oil. LCMS (ESI): m / z 270.2 (M+H)+.
[0628] Step 2: 2-(3-(2'-Fluoro-n,1'-biphenyl1-4-yl)-2-oxopiperidin-1-yl)-4-methylthiazole-5-sulfonamide (18)
[0629] Compound P18a was treated similar as described in Example 1, Step 6 to Step 7, to give compound 18 as a white solid after purification by reversed-phase flash chromatography (C18) (0.1% NH4HCO3 in water, 40 to 90% MeCN).1H-NMR (400 MHz, DMSO-d6) 67.66 (s, 2H), 7.56-7.50 (m, 3H), 7.45-7.29 (m, 5H), 4.32-4.29 (m, 1H), 4.15-4.09 (m, 2H), 2.50 (s, 3H), 2.22-2.02 (m, 4H).19F-NMR (376 MHz, DMSO-d6) 6 -118.46 (s). LCMS (ESI): m / z 446.0 (M+H)+.
[0630] Example 19: 2-(3-(3'-fluoro-[1, T-biphenyl]-4-yl)-2-oxopiperidin-1-yl)-4-methylthiazole-5-sulfonamide
[0631]
[0632] Using (3-fluorophenyl)boronic acid instead of (2-fluorophenyl)boronic acid as described in Example 18, compound 19 was obtained as a white solid.1H-NMR (400 MHz, DMSO-de) 67.68-7.66 (m, 4H), 7.54-7.47 (m, 3H), 7.37 (d, J = 8.0 Hz, 2H), 7.22-7.17 (m, 1H), 4.33-4.29 (m, 1H), 4.15-4.09 (m, 2H), 2.50 (s, 3H), 2.21-2.00 (m, 4H).19F-NMR (376 MHz, DMSO-d6) 6 -112.84 (s). LCMS (ESI): m / z 446.1 (M+H)+.
[0633] Example 20: 2-(3-(4-(Benzo[oQthiazol-7-yl)phenyl)-2-oxopiperidin-1-yl)-4-methylthiazole-5-sulfonamide
[0634]
[0635] Using benzo[d]thiazol-7-ylboronic acid instead of (2-fluorophenyl)boronic acid as described in Example 18, compound 20 was obtained as a white solid.1H-NMR (400 MHz, DMSO-d6) 59.47 (s, 1H), 8.12-8.10 (m, 1H), 7.71-7.66 (m, 4H), 7.61 (d, J = 6.8 Hz, 2H), 7.46 (d, J = 8.0 Hz, 2H), 4.34-4.31 (m, 1H), 4.18-4.11 (m, 2H), 2.50 (s, 3H), 2.26-2.05 (m, 4H). LCMS (ESI): m / z 485.1 (M+H)+.
[0636] Example 21: 2-(3-(3'-(Methoxy-c / 3)-[1,r-biphenyl]-4-yl)-2-oxopiperidin-1-yl)-4-methylthiazole-5-sulfonamide
[0637]
[0638] Using (3-(methoxy-d3)phenyl)boronic acid instead of (2-fluorophenyl)boronic acid as described in Example 18, compound 21 was obtained as a white solid.1H-NMR (400 MHz, DMSO-d6) 5 7.65-7.61 (m, 4H), 7.40-7.33 (m, 3H), 7.22 (d, J = 8.0 Hz, 1H), 7.18 (t, J = 2.0 Hz, 1H), 6.93 (dd, J = 2.4, 8.0 Hz, 1H), 4.33-4.29 (m, 1H), 4.15-4.08 (m, 2H), 2.50 (s, 3H), 2.21-2.00 (m, 4H). LCMS (ESI): m / z 461.1 (M+H)+.
[0639] Example 22: 2-(3-(2'-(Difluoromethyl)-[1, T-biphenyl]-4-yl)-2-oxopiperidin-1-yl)-4-methylthiazole-5-sulfonamide
[0640]
[0641] Using (2-(difluoromethyl)phenyl)boronic acid instead of (2-fluorophenyl)boronic acid as described in Example 18, compound 22 was obtained as a white solid.1H-NMR (400 MHz, DMSO-d6) 5 7.75 (d, J = 7.6 Hz, 1H), 7.65-7.55 (m, 4H), 7.42-7.38 (m, 3H), 7.33 (d, J = 8.4 Hz, 2H), 6.80 (t, J = 54.8 Hz, 1H), 4.32-4.29 (m, 1H), 4.17-4.09 (m, 2H), 2.50 (s, 3H), 2.25-2.01 (m, 4H).19F-NMR (376 MHz, DMSO-d6) 5 -106.87 (d, J = 3.8 Hz). LCMS (ESI): m / z 478.0 (M+H)+.
[0642] In addition, also compound 22-1 was isolated:
[0643] 2-(3-(2'-Formyl-[1, T-biphenyl]-4-yl)-2-oxopiperidin-1-yl)-4-methylthiazole-5-sulfonamide (22-1)
[0644]
[0645] 1H-NMR (400 MHz, DMSO-d6) 59.91 (s, 1H), 7.93 (dd, J = 1.2, 7.6 Hz, 1H), 7.79-7.74 (m, 1H), 7.65-7.54 (m, 4H), 7.44-7.40 (m, 4H), 4.34-4.29 (m, 1H), 4.18-4.09 (m, 2H), 2.50 (s, 3H), 2.24-2.03 (m, 4H). LCMS (ESI): m / z 456.0 (M+H)+.Example 23: 2-(3-(5'-Cyclopropyl-2'-fluoro-[1, T-biphenyl]-4-yl)-2-oxopiperidin-1-yl)-4-methylthiazole-5-sulfonamide
[0646]
[0647] Using (5-cyclopropyl-2-fluorophenyl)boronic acid instead of (2-fluorophenyl)boronic acid as described in Example 18, compound 23 was obtained as a white solid.1H-NMR (400 MHz, DMSO-d6) 6 7.66 (s, 2H), 7.78 (d, J = 6.8 Hz, 2H), 7.36 (d, J = 8.4 Hz, 2H), 7.20-7.15 (m, 2H), 7.11-7.07 (m, 1H), 4.33-4.29 (m, 1H), 4.15-4.09 (m, 2H), 2.50 (s, 3H), 2.21-1.96 (m, 5H), 0.97-0.92 (m, 2H), 0.73-0.69 (m, 2H).19F-NMR (376 MHz, DMSO-d6) 6 -123.60 (s). LCMS (ESI): m / z 486.1 (M+H)+.
[0648] Example 24: 2-(3-(2,-Chloro-5,-fluoro-[1,1,-biphenyl]-4-yl)-2-oxopiperidin-1-yl)-4-methylthiazole-5-sulfonamide
[0649]
[0650] Using (2-chloro-5-fluorophenyl)boronic acid instead of (2-fluorophenyl)boronic acid as described in Example 18, compound 24 was obtained as a white solid.1H-NMR (400 MHz, DMSO-d6) 6 7.64-7.60 (m, 3H), 7.73 (d, J = 8.0 Hz, 2H), 7.37 (d, J = 8.4 Hz, 2H), 7.36-7.26 (m, 2H), 4.33-4.29 (m, 1H), 4.15-4.08 (m, 2H), 2.51 (s, 3H), 2.23-2.01 (m, 4H).19F-NMR (376 MHz, DMSO-d6) 6 -114.98 (s). LCMS (ESI): m / z 480.1 (M+H)+.
[0651] Example 25: 2-(3-([1, T-Biphenyl]-4-yl-2,,3,,4,,5,,6,-c / 5)-2-oxopiperidin-1-yl)-4-methylthiazole-5-sulfonamide
[0652]
[0653] Using (phenyl-cfc)boronic acid instead of (2-fluorophenyl)boronic acid as described in Example 18, compound 25 was obtained as a white solid.1H-NMR (500 MHz, DMSO-de) 67.62 (d, J = 8.0 Hz, 2H), 7.51 (br s, 2H), 7.35 (d, J = 8.0 Hz, 2H), 4.32-4.28 (m, 1H), 4.15-4.08 (m, 2H), 2.50 (s, 3H), 2.21-2.17 (m, 1H), 2.10-2.00 (m, 3H). LCMS (ESI): m / z 433.1 (M+H)+.
[0654] Example 26: 2-(3-(4-(2,2-Difluorobenzo[oQ[1,3]dioxol-4-yl)phenyl)-2-oxopiperidin-1-yl)-4-methylthiazole-5-sulfonamide
[0655]
[0656] Using (2,2-difluorobenzo[d][1,3]dioxol-4-yl)boronic acid instead of (2-fluorophenyl)boronic acid as described in Example 18, compound 26 was obtained as a white solid.1H-NMR (400 MHz, DMSO-d6) 5 7.69-7.66 (m, 4H), 7.49 (d, J = 7.6 Hz, 1H), 7.45-7.49 (m, 3H), 7.32 (t, J = 8.0 Hz, 1H), 4.33-4.29 (m, 1H), 4.16-4.09 (m, 2H), 2.50 (s, 3H), 2.22-2.19 (m, 1H), 2.12-2.04 (m, 3H).19F-NMR (376 MHz, DMSO-d6) 5 -48.83 (s). LCMS (ESI): m / z 508.0 (M+H)+.
[0657] Example 27: 2-(3-(3',5'-Difluoro-2,-methoxy-[1, T-biphenyl]-4-yl)-2-oxopiperidin-1-yl)-4-methylthiazole-5-sulfonamide
[0658]
[0659] Using (3,5-difluoro-2-methoxyphenyl)boronic acid instead of (2-fluorophenyl)boronic acid as described in Example 18, compound 27 was obtained as a white solid.1H-NMR (400 MHz, DMSO-d6) 57.62 (br s, 2H), 7.50 (d, J = 8.0 Hz, 2H), 7.37-7.33 (m, 3H), 7.12 (d, J = 9.2 Hz, 1H), 4.32-4.28 (m, 1H), 4.14-4.10 (m, 2H), 3.66 (s, 3H), 2.50 (s, 3H), 2.22-2.19 (m, 1H), 2.11-2.03 (m, 3H).19F-NMR (376 MHz, DMSO-d6) 5 -115.93 (d, J = 4.5 Hz), -125.74 (d, J = 4.1 Hz). LCMS (ESI): m / z 494.1 (M+H)+.
[0660] Example 28: 2-(1-(2',5'-Difluoro-[1, T-biphenyl]-4-yl)-2-oxo-3-azabicyclo[3.1.0]hexan-3-yl)-4-methylthiazole-5-sulfonamide
[0661]
[0662] / \ / -allyl- / \ / -((4-bromophenyl)ethynyl)-4-methylbenzenesulfonamide (2.0 g; synthesis described in Chem. Commun. 2021:57;5254) was dissolved in 1,2-dichloroethane (50 mL). Tetrakis(3,5-bis(trifluoromethyl)phenyl)borate (4.7 g), Cu(CH3CN)4BF4 (1.6 g) and 8-methylquinoline 1-oxide (0.76 g) were added sequentially. The mixture was heated to 80°C and stirred for 12 h, cooled to rt, filtered through Celite, concentrated in vacuo and purified by column chromatography (PE / EtOAc = 8:2, v / v) to afford P28a as a white solid. (ESI): m / z 406.1(M+H)+.
[0663]
[0664] A mixture of P28a (1.5 g), (2,5-difluorophenyl)boronic acid (0.59 g), Na2COs (0.96 g) and Pd(dppf)Ch (96 mg) in 1,4-dioxane / H2O (5:1, v / v, 5 mL) was degassed with N2 and heated to 100°C. The mixture was stirred for 2 h, cooled to rt, concentrated and purified by column chromatography (DCM: MeOH = 97:3) to afford P28b as a yellow solid. LCMS (ESI): m / z 440.3 (M+H)+.
[0665] Step 3: 1-(2',5'-Difluoro- -one (P28c)
[0666] To a solution of compo
[0667]
[0668] were added magnesium turnings (37 mg) and saturated aqueous NH4CI (5 mL). The mixture was subjected to sonication at rt until full consumption of the starting material. After completion, the reaction was quenched with water and extracted with ethyl acetate (3 x 20 mL). The combined organic layers were washed with brine, dried over anhydrous Na2SC>4, filtered, concentrated and purified by column chromatography (PE / EtOAc) to afford compound P28c as a white solid. LCMS (ESI): m / z 286.3 (M+H)+.
[0669] Step 4: 2-(1-(2',5'-Difluoro-n, T-biphenyl1-4-yl)-2-oxo-3-azabicyclof3.1.01hexan-3-yl)-4-methylthiazole-5-sulfonamide (28)
[0670] Compound P28c was treated similar as described in Example 1, Step 6 to Step 7, to give compound 28 as a white solid after purification by reversed-phase flash chromatography (C18) (0.1% NH4HCO3 in water, 40 to 90% MeCN).1H-NMR (400 MHz, DMSO-d6) 57.70 (s, 2H), 7.62-7.57 (m, 4H), 7.46-7.36 (m, 2H), 7.30-7.25 (m, 1H), 4.24-4.20 (m, 1H), 4.13 (d, J = 7.2 Hz, 1H), 2.69-2.64 (m, 1H), 2.47 (s, 3H), 1.83-1.79 (m, 1H), 1.51 (t, J = 4.8 Hz, 1H).19F-NMR (376 MHz, DMSO-d6) 5 -118.34 (d, J = 17.7 Hz), -123.88 (d, J = 18.1 Hz). LCMS (ESI): m / z 462.0 (M+H)+.
[0671] Example 28-1 to 28-9:
[0672] By applying similar procedures as described above, the following compounds can be prepared:
[0673]
[0674]
[0675] Biological Assays
[0676] The novel compounds according to the invention exhibit an unforeseeable surprising spectrum of action, e.g. they exhibit antiviral action especially against representatives of the herpes viridae group, particularly against herpes simplex viruses (HSV). They are thus suitable for the treatment and prophylaxis of disorders which are caused by viruses especially herpes viruses, in particular disorders which are caused by herpes simplex viruses.
[0677] In-vitro Activity
[0678] Viruses and Cells:
[0679] HSV (HSV-1 clinical isolates, HSV-2 MS and HSV resistant strains; C. Gege et al. Sc / . Transl. Med. 2021;13,eabf8668) was cultivated on Vero cells (ATCC CCL-81) under the following conditions: The cells were grown in M199 medium (5% fetal calf serum, 2 mM glutamine, 100 IU / mL penicillin, 100 pg / mL streptomycin) in cell culture bottles at 37°C and 5% CO2. The cells were splitted twice per week (1:4). For the infection, the medium was removed, the cells were washed with Hank's solution, detached using 0.05% trypsin, 0.02% EDTA and incubated at a density of 4x105cells / mL under the above-mentioned conditions for 24 h. The medium was removed and the virus solution was added at an m.o.i of <0.05 in a volume of 2 mL per 175 cm2surface. The infected cells were incubated at 37°C, 5% CO2 for 1 h and then medium was added up to a volume of 50 mL per 175 cm2bottle. 3 days after the infection, the cultures showed clear signs of a cytopathic effect. The virus was released by freezing (-80°C) and thawing (37°C) the infected cultures twice. Cell debris was removed by centrifugation (300g, 10 min, 4°C) and the supernatant was frozen in aliquots at -80°C.
[0680] The virus titre was determined using a plaque assay. To this end, Vero cells were seeded in 24-well plates at a density of 4x105cells per well and, after 24 h of incubation (37°C, 5% CO2) infected with 100 pL of inoculum (dilutions (10-2to 10-12) of the virus stock). 1 h after the infection, the medium was removed and the cells were covered with 1 mL of overlay medium (0.5%methylcellulose, 0.22% sodium bicarbonate, 2 mM glutamine, 100 IU / mL penicillin, 100 pg / mL streptomycin, 5% foetal calf serum in MEM- Eagle medium with Earl's salt) and incubated for 3 days in a cell incubator (at 37°C, 5% CO2). The cells were then fixed using 4% formalin for 1 h, washed with water, stained with Giemsa for 30 min and then washed and dried. Using a plaque viewer, the virus titre was determined. The stocks used for the experiments had a titre of 1 x105 / mL up to 1x108 / mL.
[0681] The antiviral action was determined using an activity selectivity assay as described in DE10235967, W02004 / 015416 and in the paper [G. Kleymann et al. J. Biomol. Screen.
[0682] 2004;9,578\ in 96- or 384-well mictrotitre plates using various cell lines of neuronal, lymphoid and epithelial origin, such as, for example, Vero (african green monkey kidney cells), MEF (murine embryonal fibroblasts), HELF (human embryonal fibroblasts), NT2 (human neuronal cell line) or Jurkat (human lymphoid T-cell line). The relevant experimental details of the assay, as described in the above-mentioned patent and publication, to evaluate the antiviral activity of the invention (disclosed compounds) are described below.
[0683] The effect of the substances on the spreading of the cytopathogenic effect was determined in comparison to the reference compound acyclovir-sodium (Zovirax™), a clinically approved antiherpes chemotherapeutic.
[0684] The compounds (50 mM stock solution dissolved in DMSO) are examined on microtiter plates (for example 96-well flat bottom cell culture plates) at a final concentration of 250 to 0.5 pM or, in case of potent antiviral compounds, 250 to 0.5 nM in 2 to 4 replications (4 to 2 substances per plate). Also examined are toxic and cytostatic effects or precipitation of the compounds. After an appropriate dilution of the compounds (1:2) on the microtitre plate in the appropriate medium (100 pL), a suspension of cells (50 pL, 1 x104cells per well), such as, for example of Vero cells in DMEM or M 199 (medium 199 with 5% foetal calf serum, 2 mM glutamine and optionally 100 lU / mL penicillin and 100 pg / mL streptomycin) or of MEF or HELF cells in EMEM (Eagle's Minimum Essential Medium with 10% foetal calf serum, 2 mM glutamine and optionally 100 lU / mL penicillin and 100 pg / mL streptomycin), or of NT2- and Jurkat cells in DMEM ((4.5 mg / L glucose plus pyridoxin) with 10% foetal calf serum, 2 mM glutamine, 1 mM sodium pyruvate, non-essential amino acids and optionally 100 lU / mL penicillin and 100 pg / mL streptomycin) is added to each well and the cells in the relevant wells are infected with the appropriate amount of virus (HSV-1 or HSV-2 having an m.o.i (multiplicity of infection) of 0.0025 for Vero, HELF and MEF cells, and an m.o.i. of 0.1 for NT2 and Jurkat cells). The plates are then incubated at 37°C in a cell CO2 incubator (5% CO2) for several (5-6) days. After this time, the cell lawn of, for example, Vero cells in the substance-free virus controls, starting from 25 infections centres, is completely destroyed or lysed by the cytopathogenic effect (CPE) of the herpes viruses (100% CPE). The plates are initially evaluated visually using a microscope and then analysed using a fluorescent dye or naphthol black-blue. To this end, in case of a fluorescent dye, the cell supernatant of all wells of the MTP is aspirated and the wells are filled with 250 pL PBS (phosphate buffered saline) wash solution. The PBS is then aspirated and all the wells are filled with 200 pL of fluorescent dye solution (fluorescein diacetate, 10 pg / mL in PBS). After an incubation time of 30 to 90 min, the test plates are read in a fluorescence detector at an excitation wavelength of 485 nm and anemission wavelength of 538 nm. In case of naphthol black-blue, the cell culture supernatants were removed from the wells and the cells were fixed with 100 pL / well of a 4 % (v / v) paraformaldehyde for 30 min at room temperature. The cells not lysed by the virus were then stained with 100 pL / well of a naphthol black-blue solution (0.05 % (w / v) in 0.82 % (v / v) sodium acetate, 9 % (v / v) acetic acid). Excess dye was washed out. 100 pL of a 0.1 M NaOH elution solution was added to each well to solve the dye from stained cells. Photometric data acquisition of the eluted stain was carried out with a UV-VIS reader and the associated SoftMaxPro software (version 5.01) at a wavelength of 630 nm. Here, IC50 is the half-maximal fluorescence or absorption intensity with respect to the non-infected cell control (100% value). The IC50 value [%] ((compound treated infected cells minus non treated virus infected cells) divided by (cell control or Zovirax treated infected cells minus non treated infected cells) x 100) can also be referenced to a suitable active compound control (see description of the assay: infected cells in the presence of suitable concentrations of an antiviral compound such as, for example, Zovirax 20 pM). This active compound control reaches fluorescence intensities of about 85 to 100% with respect to the noninfected cell control. The results (antiviral activity in infected Vero cell culture) for some Example compounds, comprising a mixture of the respective enantiomers as well as of the separated isomers of Examples above are summarized in TABLE 1A below.
[0685] TABLE 1A
[0686]
[0687] Therein, Table 1A further provides the assay data for exemplified compounds grouped via the following ranges: +++ indicating IC50 <100 nM, ++ indicating an IC50 of >100 to <1000 nM and + indicating an IC50 of >1 to <10 pM.
[0688] In a similar alternative PRA assay the following cells and viruses were used: HSV-1: VI RO-FR #1510485 (R) and HSV-2 - VIRO-FR #1316658 (S) were selected for testing theirsusceptibility against compounds (Examples 16, 16-1, 17, 17-1, 23 and 28) of the present invention in a plaque reduction assay (PRA). HSV-1 and HSV-2 clinical isolates were cultured, viral stocks generated and titrated to determine the concentration of plaque forming units (PFU). Vero cells were seeded in 24-well plates and infected 24 hours later with different HSV-1 and HSV-2 isolates at a multiplicity of infection (MOI) of 0.0025 using centrifugal enhancement (30 minutes at 2300 rpm). After 1 additional hour of incubation at 37°C, the infected cells were overlaid with 1.5% Avicel / 5% FCS DM EM solution containing serial two-fold dilutions of a compound of the present invention. The compound was tested in duplicates at 11 concentrations alongside a virus control without treatment. Following 4 days of incubation, cells were fixed with 3.7% formaldehyde and stained with ethyl violet. Plaques were counted, normalized to determine antiviral activity (%) and IC50 values were determined by a nonlinear plot of antiviral activity as a function of drug concentration (IC50: log (inhibitor) versus response (variable slope (four parameters)), IC90: log (inhibitor) versus response (find EC Anything, least squares fit)) using GraphPad Prism version 11. The results for some Example compounds above are summarized in TABLE 1B below.
[0689] TABLE 1B
[0690]
[0691] Therein, Table 1B provides the assay data for further exemplified compounds grouped via the following ranges: +++ indicating IC50 <100 nM, ++ indicating an IC50 of >100 to <1000 nM and + indicating an IC50 of >1 to <10 pM.In-vivo Activity
[0692] Brain-to-Plasma Exposure in Mouse Cassette Pharmacokinetic Study:
[0693] The brain and plasma exposure for cyclic amide Example 1A, Example 2A as well as for Example 5C and for its cyclic urea matched-pair (Comparative Example C1 = Compound 1 from W02024 / 047508 and WO2024 / 224304 = ABI-5366) was assessed in two female groups with 3 mice (strain C57BL / 6, 8 weeks old) after oral cassette dosing with a dose of 10 mg / kg. After 2 h and 4 h post dose, the animals were sacrificed and perfused with phosphate-buffered saline (PBS) until PBS was transparent and brain was collected and stored.
[0694] The compounds were formulated in 5% DMSO and 95% aq. hydroxypropyl methylcellulose (HPMC) (0.5% in PBS pH 7.4) with an application volume of 5 mL / kg resulting in a milky suspension. All animals showed a normal behaviour and there were no clinical signs observed after dosing. Blood samples (about 500 pL) were collected from the retrobulbar venous plexus. Li-heparin was used as anticoagulant. Blood samples were centrifuged at 6800 ref for 8 minutes at 4°C to generate plasma. Samples were frozen immediately and stored at -80°C until LC-MS analysis. The data obtained are as follows (with standard deviation):
[0695] Example 1A Example 2A Example 5C Comparative Example C1 mean plasma cone. [pM] after 2 h 11.0 ± 0.8 20.9 ±0.7 10.1 ± 1.1 4.5 ± 1.1 mean brain cone, [pmolal] after 2 h 5.5 ± 0.5 7.4 ± 0.8 5.8 ± 0.3 0.088 ± 0.009 brain-to-plasma ratio (2 h)
[0696]
[0697] 0.50 ± 0.08 0.35 ± 0.03 0.58 ± 0.09 0.020 ± 0.004 mean plasma cone. [pM] after 4 h 10.3 ± 0.7 18.0 ±0.4 8.8 ± 0.4 4.2 ± 0.5 mean brain cone, [pmolal] after 4 h 6.2 ±0.5 8.5 ±1.0 6.3 ± 0.6 0.120 ± 0.005 brain-to-plasma ratio (4 h) 0.60 ± 0.01 0.47 ±0.05 0.72 ±0.10 0.029 ± 0.005 The brain-to-plasma ratio is surprisingly improved in the cyclic amides of the present invention compared to the cyclic urea matched-pair (Comparative Example C1) after 2 and 4 h, respectively, irrespective of whether the cyclic amides of the present invention contain a primary sulfonamide or a sulfoximine moiety. A high brain-to-plasma ratio together with a high brain exposure is beneficial in the treatment of e.g. herpes encephalitis or Alzheimer disease.
[0698] Summary
[0699] Preference is given to antiviral compounds according to the invention whose IC50 (HSV-1 / Vero) in the activity selectivity assay described above is preferably below 100 pM, more preferably below 10 pM and very particularly perferable below 1 pM.
[0700] Examples of indication areas which may be mentioned are:
[0701] 1) Treatment and prophylaxis of herpes infections, in particular herpes simplex infections in patients displaying herpes disease such as herpes labialis, herpes genitalis and herpes- related keratitis, viral meningitis (e.g. Mollaret's meningitis), Alzheimer’s disease, herpes encephalitis, disseminated disease, pneumonia, hepatitis or viral shedding etc.2) Treatment and prophylaxis of herpes infections, in particular herpes simplex infections, in patients with a suppressed immune system (for example AIDS patients, cancer patients, patients having a genetic or inherited immunodeficiency, transplant patients).
[0702] 3) Treatment and prophylaxis of herpes infections, in particular herpes simplex infections, in new-born children and infants
[0703] 4) Treatment and prophylaxis of herpes infections, in particular herpes simplex infections, and in herpes-positive patients, in particular herpes-simplex-positive patients, for suppressing recurrence or viral shedding (suppression therapy).
[0704] 5) Treatment and prophylaxis of herpes infections, in particular herpes simplex infections, and in herpes-positive patients, in particular herpes-simplex-positive patients, resistant to nucleosidic antiviral therapy such as acyclovir, penciclovir, famciclovir, ganciclovir, valacyclovir etc. or phosphonates such as foscavir.
[0705] In this respect reference is further made to the indication areas and methods of use described in the general specification.
Claims
CLAIMS:
1. A compound represented by Formula (I)an enantiomer, diastereomer, tautomer, isotopic variant, / V-oxide, solvate and pharmaceutically acceptable salt thereof, whereinL is a group forming a saturated or partially saturated C4-io-membered heterocycloalkyl- ring or a 6-membered heteroaryl-ring being characterized by the ring-forming group [- C-C(=O)-N-], wherein said ring L can optionally contain 1 or 2 additional heteroatoms selected from O, S or N, and wherein the heterocycloalkyl- and heteroaryl-ring “L” can optionally carry 1 to 4 additional substituents independently selected from the group consisting of oxo, -CN, -NO2, -OR11, -O-C2-6-alkylene-OR11, -Ci-6-alkyl, halo-Ci-6-alkyl, halogen, -CO2R11, -C(=O)NR11R12, -C(=O)NR11SO2R11, -C(=O)R11, -SR11, -SOXR11, - SO3R11, P(=O)(OR11)2, -SO2NR11R12, -NR11C(=O)R11, -NR11SO2R13, NR11C(=O)NR11R12, -NR11SO2NR11R12, -C3-io-cycloalkyl, -0-C3-io-cycloalkyl, -C3-io- heterocycloalkyl, -0-C3.io-heterocycloalkyl and -NR11R12;X is selected fromR1is selected from H, halogen, -Ci-6-alkyl, halo-Ci-6-alkyl, -C3-6-cycloalkyl, halo-C3-6- cycloalkyl, -O-Ci-6-alkyl, -O-halo-Ci-6-alkyl and -NH-Ci-6-alkyl;R2is selected from H, -CN, -NO2, -Ci-10-alkyl, -C2- -alkenyl, -C2- -alkynyl, -Co-10-alkylene- C3-io-cycloalkyl, -Co-io-alkylene-C3-io-heterocycloalkyl, -Co-w-alkylene-(5- to 10- membered heteroaryl), -Co-w-alkylene-(6- to 10-membered aryl), -Co-w-alkylene-OR11, -Co-io-alkylene-C02R11, -Co-io-alkylene-C(=0)NR11R12, -CO-io-alkylene-C(=S)NR11R12, - Co-io-alkylene-C(=0)NR11S02R13, -Co-io-alkylene-C(=S)NR11S02R11, -Co-w-alkylene- C(=O)R11, -Co-w-alkylene-C(=S)R11, -Co-10-alkylene-SR11, -Co-io-alkylene-SOxR13, -Co- io-alkylene-S03R11, -Co-io-alkylene-S02NR11R12, -Co-io-alkylene-NR11C(=0)R11, -Co-10- alkylene-NR11C(=S)R11, -Co-io-alkylene-NR11S02R13, -Co-10-alkylene- NR11C(=O)NR11R12, -CO-io-alkylene-NR11C(=S)NR11R12, -Co-10-alkylene- NR11SO3NR11R12, -Co-w-alkylene-NR11R12, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, -CN, -NO2, - OR11, -O-C2-6-alkylene-OR11, -Ci-6-alkyl, halo-Ci-6-alkyl, halogen, -CO2R11, -C(=O)NR11R12, -C(=O)NR11SO2R11, -C(=O)R11, -SR11, -SOXR11, -SO3R11, - P(=O)(OR11)2, -SO2NR11R12, -NR11C(=O)R11, -NR11SO2R13, -NR11C(=O)NR11R12, - NR11SO2NR11R12, -Cs-w-cycloalkyl, -O-Cs-w-cycloalkyl, -C3-10-heterocycloalkyl, -O-C3- 10-heterocycloalkyl and -NR11R12;R3is selected from H, -Ci-6-alkyl, halo-Ci-6-alkyl, -O-Ci-6-alkyl, -O-halo-Ci-6-alkyl, -C3-6- cycloalkyl and -C3-6-heterocycloalkyl, wherein alkyl, cycloalkyl and heterocycloalkyl are optionally substituted with 1 to 5 substituents independently selected from halogen, - CN, -OH, oxo, -C1-3-alkyl, halo-C1-3-alkyl, -O-Ci-3-alkyl, -O-halo-Ci-3-alkyl, -SO2-Ci-3- alkyl, -CO2H;or R2and R3when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, - CN, -NO2, -OH, oxo, -C1-3-alkyl, halo-C1-3-alkyl, -O-Ci-3-alkyl, -O-halo-Ci-3-alkyl, -SO2- Ci-3-alkyl, -CO2H;R5and R6are independently selected from H, halogen, -Ci-6-alkyl, -NH2, -NHCi-6-alkyl, - N(Ci-6-alkyl)2, -C0-6-alkylene-C(=O)NH2;or R5and R6independently when taken together with the carbon to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, -CN, -NO2, -OH, oxo, -C1-3-alkyl, halo-C1-3-alkyl, -O-C1-3-alkyl, -O-halo-C1-3-alkyl, -SO2-Ci-3-alkyl, -CO2H;R7is selected from a phenyl and 5- or 6-membered heteroaryl, wherein phenyl and heteroaryl are optionally substituted with 1 to 4 substituents independently selected from halogen, -CN, -NO2, -OH, -Ci-6-alkyl, -O-Ci-6-alkyl, -C3-6-cycloalkyl, -O-C3-6- cycloalkyl, -C3-6-heterocycloalkyl, -O-C3-6-heterocycloalkyl, -SOy-Ci-6-alkyl, -CO2H, - C(=O)O-Ci-6-alkyl, 6- to 10-membered aryl, 5- to 10-membered heteroaryl, -O-(6- to 10-membered aryl) and -O-(5- to 10-membered heteroaryl), whereinalkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are optionally substituted with 1 to 5 substituents independently selected from halogen, -CN, -NO2, -OH, -R13, -OR13, - CO2R11, -NR11R12, -C(=O)R11, -C(=S)R11, -C(=O)NR11R12, -NR11C(=O)NR11R12, - NR11C(=O)OR13, -OC(=O)NR11R12, -C(=S)NR11R12, -NR11C(=S)NR11R12, - NR11C(=S)OR13, -OC(=S)NR11R12; -SOy-C1-6-alkyl, -SOy-halo-C1-6-alkyl, -SR11, - SOxR13, -SO3R11, -SO2NR11R12, -NR11SO2R13, -NR11SO2NR11R12;R8is independently selected from H, -CN, -NO2, -Ci-10-alkyl, -C2- -alkenyl, -C2- -alkynyl, -Co-w-alkylene-Cs-io-cycloalkyl, -Co-io-alkylene-Cs- -heterocycloalkyl, -Co-w-alkylene-(5 to 10-membered heteroaryl), -Co-w-alkylene-(6 to 10-membered aryl), -Co-10-alkylene- OR11, -Co-w-alkylene-C02R11, -Co-w-alkylene-C(=0)NR11R12, -Co-10-alkylene-C(=S)NR11R12, -Co-io-alkylene-C(=0)NR11S02R13, -Co-io-alkylene-C(=S)NR11S02R11, - Co-w-alkylene-C(=0)R11, -Co-w-alkylene-C(=S)R11, -Co-w-alkylene-SR11, -Co-10- alkylene-SOx-R13, -Co-w-alkylene-SOsR11, -Co-io-alkylene-S02NR11R12, -Co-w-alkylene- NR11C(=O)R11, -Co-io-alkylene-NR11C(=S)R11, -Co-io-alkylene-NR11S02R11, -Co-10- alkylene-NR11C(=O)NR11R12, -Co-io-alkylene-NR11C(=S)NR11R12, -Co-10-alkylene-NR11- SO2-NR11R12, -Co-w-alkylene-NR11R12, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, -CN, -NO2, - OR11, -O-C2-6-alkylene-OR11, -Ci-6-alkyl, halo-Ci-6-alkyl, halogen, -CO2R11, - CONR11R12, -CONR11SO2R11, -COR11, -SOXR11, -SO3H, -PO(OH)2, -SO2NR11R12, - NR11COR11, -NR11SO2R11, -NR11-CO-NR11R12, -NR11-SO2-NR11R12, -C3-io-cycloalkyl, - O-Cs-w-cycloalkyl, -C3-10-heterocycloalkyl, -O-C3-10-heterocycloalkyl and -NR11R12; R9is selected from -Ci-10-alkyl, -C2- -alkenyl, -C2- -alkynyl, -Co- -alkylene-Cs-io- cycloalkyl, -Co-io-alkylene-Cs- -heterocycloalkyl, -Co-w-alkylene-(5- to 10-membered heteroaryl), -Co-w-alkylene-(6- to 10-membered aryl), -Co-w-alkylene-OR11, -C0-10- alkylene-CO2R11, -Co-io-alkylene-C(=0)NR11R12, -CO-io-alkylene-C(=S)NR11R12, -C0-10- alkylene-C(=O)NR11SO2R13, -Co-io-alkylene-C(=S)NR11S02R11, -Co-10-alkylene- C(=O)R11, -Co-w-alkylene-C(=S)R11, -Co-10-alkylene-SR11, -Co-io-alkylene-SOxR13, -Co- io-alkylene-S03R11, -Co-io-alkylene-S02NR11R12, -Co-io-alkylene-NR11C(=0)R11, -Co-10- alkylene-NR11C(=S)R11, -Co-io-alkylene-NR11S02R13, -Co-10-alkylene- NR11C(=O)NR11R12, -CO-io-alkylene-NR11C(=S)NR11R12, -Co-10-alkylene- NR11SO2NR11R12, -Co-w-alkylene-NR11R12, wherein alkyl, alkenyl, alkynyl, alkylene, cycloalkyl, heterocycloalkyl, aryl and heteroaryl is unsubstituted or substituted with 1 to 7 substituents independently selected from the group consisting of oxo, -CN, -NO2, - OR11, -O-C2-6-alkylene-OR11, -Ci-6-alkyl, halo-Ci-6-alkyl, halogen, -CO2R11, - C(=O)NR11R12, -C(=O)NR11SO2R11, -C(=O)R11, -SR11, -SOXR11, -SO3R11, - P(=O)(OR11)2, -SO2NR11R12, -NR11C(=O)R11, -NR11SO2R13, -NR11C(=O)NR11R12, - NR11SO2NR11R12, -Cs-w-cycloalkyl, -O-Cs-w-cycloalkyl, -C3-10-heterocycloalkyl, -O-C3- 10-heterocycloalkyl and -NR11R12;R11is independently selected from H, -Ci-6-alkyl, -C0-6-alkylene-C3-10-cycloalkyl and -Co-6- alkylene-Cs-io-heterocycloalkyl, wherein alkyl, alkylene, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 6 substituents independently selected from the group consisting of halogen, -CN, -OH, oxo, -C1-3-alkyl, halo-C1-3-alkyl, -O-Ci-3-alkyl, - O-halo-Ci-3-alkyl, -NH2, -NH(C1-3-alkyl), -N(C1-3-alkyl)2, -C3-6-heterocycloalkyl, -C3-6- cycloalkyl, -SO2-NHC1-3-alkyl, -SO2-N(C1-3-alkyl)2and -SO2-C1-3-alkyl, wherein cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of F, -OH, oxo, -CH3, -CHF2and - CF3;R12is independently selected from H, -Ci-6-alkyl, halo-Ci-6-alkyl and -C3-6-cycloalkyl;or R11and R12when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing 1 or 2 heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of halogen, - CN, -NO2, -OH, oxo, -C1-3-alkyl, halo-C1-3-alkyl, -O-Ci-3-alkyl, -O-halo-Ci-3-alkyl, -SO2- Ci-3-alkyl, -CO2H;R13is independently selected from -Ci-6-alkyl, -C2-6-alkenyl, -C2-6-alkynyl, -Co-6-alkylene-C3- 10-cycloalkyl and -Co-6-alkylene-C3- -heterocycloalkyl, wherein alkyl, alkylene, cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 6 substituents independently selected from the group consisting of halogen, -CN, -OH, oxo, -C1-3-alkyl, halo-C1-3-alkyl, -O-Ci-3-alkyl, -O-halo-Ci-3-alkyl, -NH2, -NH(Ci-3-alkyl), -N(Ci-3-alkyl)2, - C3-6-heterocycloalkyl,- C3-6-cycloalkyl, -SO2-NHCi-3-alkyl, -SO2-N(Ci-3-alkyl)2 and -SO2- Ci-3-alkyl, wherein cycloalkyl and heterocycloalkyl is unsubstituted or substituted with 1 to 3 substituents independently selected from the group consisting of F, -OH, oxo, - CH3, -CHF2and -CF3;n is selected from 0 and 1;x is independently selected from 1 and 2;y is independently selected from 0, 1 and 2;wherein the following compounds are excluded2. The compound according to claim 1, an enantiomer, diastereomer, tautomer, isotopic variant, / V-oxide, solvate and pharmaceutically acceptable salt thereof, whereinX is selected from the group consisting ofand wherein L, R1, R2, R3, R5, R6, R5’, R6’, R7, R8, R9, R11, R12, R13, n, x and y have the meaning as defined in claim 1.
3. The compound according to claim 1 or 2, an enantiomer, diastereomer, tautomer, isotopic variant, / V-oxide, solvate and pharmaceutically acceptable salt thereof, whereinR5and R6are independently selected from H and Ci-3-alkyl;R7is selected from a phenyl and 5- or 6-membered heteroaryl, wherein phenyl and heteroaryl are optionally substituted with 1 to 3 substituents independently selectedfrom halogen, OH, Me (-CH3), OMe (-O-CH3), CHF2, CF3, OCHF2, OCF3, and wherein the phenyl or 5- or 6-membered heteroaryl carries a 6- to 10-membered aryl or a 5- to 10-membered heteroaryl, wherein said 6- to 10-membered aryl or a 5- to 10-membered heteroaryl is optionally substituted with 1 to 5 substituents independently selected from halogen, -CN, -NO2, OH, R13, OR13, CO2R11, NR11R12, C(=O)R11, C(=S)R11, C(=O)NR11R12, NR11C(=O)NR11R12, NR11C(=O)OR13, OC(=O)NR11R12, C(=S)NR11R12, NR11C(=S)NR11R12, NR11C(=S)OR13, OC(=S)NR11R12; SOy-C1-6-alkyl, SOy-halo-Ci-6- alkyl, SR11, SOXR13, SO3R11, SO2NR11R12, NR11SO2R13, NR11SO2NR11R12; and wherein the remaining substituents have the meaning as defined in claim 1 and 2.
4. The compound according to any one of the preceding claims, an enantiomer, diastereomer, tautomer, isotopic variant, / V-oxide, solvate and pharmaceutically acceptable salt thereof, whereinR7is phenyl, substituted with 1 to 4 substituents (Rx), wherein the 1 to 4 substituents Rxmay independently have the meaning of the possible substituents of R7as defined in any of the preceding claims and which is represented by Formula (II)and wherein the remaining substituents have the meaning as defined in the preceding claims.
5. The compound according to any one of the preceding claims, an enantiomer, diastereomer, tautomer, isotopic variant, / V-oxide, solvate and pharmaceutically acceptable salt thereof, whereinR7is selected from the following groups6. The compound according to any one of the preceding claims, an enantiomer, diastereomer, tautomer, isotopic variant, / V-oxide, solvate and pharmaceutically acceptable salt thereof, whereinR7is selected from the following groups7. The compound according to any one of the preceding claims, an enantiomer, diastereomer, tautomer, isotopic variant, / V-oxide, solvate and pharmaceutically acceptable salt thereof, whereinR7is selected from the following groupspreferably selected from8. The compound according to any one of the preceding claims, an enantiomer, diastereomer, tautomer, isotopic variant, / V-oxide, solvate and pharmaceutically acceptable salt thereof, whereinX is selected fromR1is independently selected from H, halogen, Ci-6-alkyl, halo-Ci-6-alkyl, C3-6-cycloalkyl, halo-C3-6-cycloalkyl, -O-Ci-6-alkyl, -O-halo-Ci-6-alkyl and -NH-Ci-6-alkyl.
9. The compound according to any one of the preceding claims, an enantiomer, diastereomer, tautomer, isotopic variant, / V-oxide, solvate and pharmaceutically acceptable salt thereof, whereinis selected from the following groups10. The compound according to any one of the preceding claims, an enantiomer, diastereomer, tautomer, isotopic variant, / V-oxide, solvate and pharmaceutically acceptable salt thereof, wherein11. The compound according to any one of the preceding claims, an enantiomer, diastereomer, tautomer, isotopic variant, / V-oxide, solvate and pharmaceutically acceptable salt thereof, whereinR2and R3are independently selected from H, Ci-3-alkyl, halo-Ci-3-alkyl, -O-Ci-3-alkyl, -O- fluoro-Ci-3-alkyl, C3-6-cycloalkyl and C3-6-heterocycloalkyl, wherein alkyl, cycloalkyl andheterocycloalkyl are optionally substituted with 1 to 5 substituents independently selected from F, Cl, OH, oxo, Me (-CH3), CHF2and CF3;or R2and R3when taken together with the nitrogen to which they are attached complete a 5- to 6-membered ring containing carbon atoms and optionally containing one heteroatoms selected from O, S or N, wherein the ring is unsubstituted or substituted with 1 to 4 substituents independently selected from the group consisting of F, Cl, OH, oxo, Me (-CH3), CHF2and CF3;R8is selected from H, -CN, -NO2, OH, C1-3-alkyl, O-C1-3-alkyl, fluoro-C1-3-alkyl and O-fluoro-C1-3-alkyl,R9is selected from C1-3-alkyl, t-butyl, fluoro-C1-3-alkyl and -cyclopropyl.
12. The compound according to any one of the preceding claims, an enantiomer, diastereomer, tautomer, isotopic variant, / V-oxide, solvate and pharmaceutically acceptable salt thereof, wherein n is 0.
13. The compound according to any one of the claims 1 to 12, wherein the compound is selected fromor an enantiomer, diastereomer, tautomer, isotopic variant, N-oxide, solvate and pharmaceutically acceptable salt thereof.
14. The compound according to any one of the claims 1 to 12, wherein the compound is selected fromor an enantiomer, diastereomer, tautomer, isotopic variant, N-oxide, solvate and pharmaceutically acceptable salt thereof.
15. The compound according to any one of the preceding claims, including an enantiomer, diastereomer, tautomer, isotopic variant, / V-oxide, solvate and pharmaceutically acceptable salt thereof, for the use as a medicament.
16. The compound according to any one of the claims 1 to 14, including an enantiomer, diastereomer, tautomer, isotopic variant, / V-oxide, solvate and pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of a disease or disorder associated with viral infections.
17. The compound, including an enantiomer, diastereomer, tautomer, isotopic variant, / V-oxide, solvate and pharmaceutically acceptable salt thereof, for the use according to claim 16, wherein the disease or disorder is associated with viral infections caused by herpes viruses, such as in particular by Herpes simplex viruses.
18. The compound according to any one of the claims 1 to 14, including an enantiomer, diastereomer, tautomer, isotopic variant, / V-oxide, solvate and pharmaceutically acceptable salt thereof, for use in the treatment or prophylaxis of neurodegenerative diseases caused by viruses, in particular caused by herpes viruses, such as in particular by Herpes simplex viruses, wherein the neurodegenerative disease is preferably Alzheimer's disease.
19. The compound, including an enantiomer, diastereomer, tautomer, isotopic variant, / V-oxide, solvate and pharmaceutically acceptable salt thereof, for the use according to any one of the claims 15 to 18, for the use in the treatment and prophylaxis of herpes infections, in particular Herpes simplex infections, in patients displaying Herpes labialis, Herpes genitalis and Herpes-related keratitis, Herpetic esophagitis, Herpetic pneumonia, viral meningitis (e.g. Mollaret's meningitis), Alzheimer’s disease, encephalitis, or hepatitis; in patients with a suppressed immune system, such as AIDS patients, cancer patients, patients having a genetic immunodeficiency, transplant patients; in new-born children and infants; in Herpespositive patients, in particular Herpes-simplex-positive patients, for suppressing recurrence or viral shedding (suppression therapy); in patients, in particular in Herpes-positive patients, in particular Herpes-simplex-positive patients, who are resistant to nucleosidic antiviral therapy such as acyclovir, penciclovir, famciclovir, ganciclovir, valacyclovir and / or compounds such as the phosphonates foscarnet or cidofovir.
20. A pharmaceutical composition comprising one or more of the compounds according to any one of the claims 1 to 14, including an enantiomer, diastereomer, tautomer, isotopic variant, / V-oxide, solvate and pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier and / or excipient and / or at least one further active substance being effective in treating a disease or disorder associated with viral infections (antiviral active compounds).
